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PREDICTORS OF CONTRALATERAL BREAST CANCER IN BRCA NEGATIVE 
WOMEN 
Publication No. _______ 
Ann Simmons, B.S. 
Supervisory Professor: Banu Arun, M.D.  
Breast cancer is the most common cancer diagnosis and second leading cause of 
death in women. Risk factors associated with breast cancer include: increased age, alcohol 
consumption, cigarette smoking, white race, physical inactivity, benign breast conditions, 
reproductive and hormonal factors, dietary factors, and family history. Hereditary breast and 
ovarian cancer syndrome (HBOC) is caused by mutations in the BRCA1 and BRCA2 genes. 
Women carrying a mutation in these genes are at an increased risk to develop a second 
breast cancer. Contralateral breast cancer is the most common second primary cancer in 
patients treated for a first breast cancer. Other risk factors for developing contralateral breast 
cancer include a strong family history of breast cancer, age of onset of first primary breast 
cancer, and if the first primary was a lobular carcinoma, which has an increased risk of 
being bilateral.  
A retrospective chart review was performed on a select cohort of women in an IRB 
approved database at MD Anderson Cancer Center. The final cohort contained 572 women 
who tested negative for a BRCA1 or BRCA2 mutation, had their primary invasive breast 
cancer diagnosed under the age of 50, and had a BRCAPro risk assessment number over 
10%. Of the 572 women, 97 women developed contralateral breast cancer. A number of 
predictors of contralateral breast cancer were looked at between the two groups. Using 
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univariable Cox Proportional Hazard model, thirteen statistically interesting risk factors 
were found, defined as having a p-value under 0.2. Multivariable stepwise Cox Proportional 
Hazard model found four statistically significant variables out of the thirteen found in the 
univariable analysis. In our study population, the incidence of contralateral breast cancer 
was 17%. Four statistically significant variables were identified. Undergoing a prophylactic 
mastectomy was found to reduce the risk of developing contralateral breast cancer, while not 
having a prophylactic mastecomy, a young age at primary diagnosis, having a positive 
estrogen receptor status of the primary tumor, and having a family history of breast cancer 
increased a woman’s risk to develop contralateral breast cancer.  
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BACKGROUND 
 
BREAST CANCER FACTS 
Breast cancer is the most common cancer diagnosis and second leading cause of 
death in women. It represents 32% of all newly diagnosed cancers and 15% of all deaths 
from cancer in women [1].  An average of 180,000 women per year in the United States will 
be diagnosed with breast cancer [2]. There are currently more than 2.4 million women in the 
United States who have a history of breast cancer [3]. Breast cancer can occur in three 
familial clusterings: sporadic, familial, and hereditary. Approximately 75% of breast cancer 
is considered sporadic, while 20% is considered familial and 5% is considered hereditary.  
Lifestyle, demographic, and personal medical history risk factors have been identified to 
help protray a women's risk to develop breast cancer. 
 
BREAST CANCER RISK FACTORS 
The high prevalence of breast cancer in the general population has led to numerous 
studies that have tried to identify factors that predispose a woman to developing breast 
cancer. Many of these predictors that are thought to increase an individuals risk of breast 
cancer have been extensively studied. Those risk factors associated with breast cancer 
include, but are not limited to: increased age, alcohol consumption, being Caucasian, 
physical inactivity, benign breast conditions, dietary factors, and family history [1]. Li et al 
(2011) found that diabetic women have a 15-20% increased risk of developing breast cancer 
over non-diabetic women. Another study found that having a healthy diet can actually lower 
a woman's risk to develop breast cancer [4].  Some reproductive factors found to be risk 
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factors for breast cancer include early age at menarche, late age at menopause, and 
nulliparity [5].  
Environmental exposures to radiation, have also been associated with a higher risk 
for developing breast cancer [1]. Gao et al (2003) suggests that all women diagnosed with 
early-stage breast cancer should avoid unnecessary radiation exposure so as to lower their 
risk of developing contralateral breast cancer.   
Of the 5% of breast cancer considered hereditary, the majority of increased risk is 
associated with mutations in the BRCA1 or BRCA2 genes. However, there are other 
syndromes that can cause an increased risk of breast cancer including Li Fraumeni 
syndrome, PTEN, and heterozygous Ataxia Telangiectasia [6]. Since these syndromes are 
rarer, Hereditary Breast and Ovarian Cancer Syndrome caused by mutations in BRCA1 and 
BRCA2  is looked at more closely and is more commonly tested for in the breast cancer 
population. 
 
HEREDITARY BREAST AND OVARIAN CANCER SYNDROME 
 Hereditary breast and ovarian cancer (HBOC) is caused by mutations in the BRCA1 
and BRCA2 genes.  Approximately 0.1% of the population carries a mutation in either 
BRCA1 or BRCA2 [7]. Almost 10% of women diagnosed with breast cancer in Poland carry 
a genetic mutation that causes them to develop their cancer [8] and there are other genetic 
isolates such as Ashkenazi Jewish women or women from Iceland. Women with mutations 
in either BRCA1 or BRCA2 are at a higher risk to develop breast cancer, especially at a 
younger age [8]. There is a 47-66% lifetime risk of breast cancer in BRCA1 mutation 
carriers and a 40-57% lifetime risk of breast cancer in BRCA2 mutation carriers [7]. There 
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have been numerous studies that have found that the breast cancer found in BRCA1 mutation 
carriers has a different pathology than breast cancer found in BRCA2 mutation carriers. 
BRCA1 mutation-caused breast cancer has a higher frequency of being a basal epithelial 
phenotype and is usually associated with estrogen receptor (ER) negative, progesterone 
receptor (PR) negative and HER2/neu negaitve breast cancer. In contrast, BRCA2 mutation-
caused breast cancer has a higher frequency of being estrogen receptor (ER) positive and 
progesterone receptor (PR) positive [5].  
 
HBOC GENETIC TESTING AND SCREENING RECOMMENDATIONS 
There are certain criteria set forth to determine which women should be offered 
BRCA mutation testing. The US Preventative Services Task Force has a strict set of 
guidelines aimed at determining which women should receive genetic testing. These 
guidlines are:  
"two first-degree relatives with breast cancer, with one diagnosed at or before age 50 
years; three or more first-or second-degree relaitves with breast cancer regardless of 
age at diagnosis; a combination of both breast and ovarian cancers among first- and 
second-degree relatives; a first-degree relative with bilateral breast cancer; two or 
more first- or second-degree relatives with ovarian cancer regardless of age at 
diagnosis; a first- or second-degree relative with both breast and ovarian cancers at 
any age; a history of breast cancer in a male relative; or a women of Ashkenazi 
Jewish heritage with any first-degree relative (or any two second-degree relatives) 
with breast or ovarian cancer" [9]. 
These guidelines help the clinician determine who should be tested for a BRCA mutation.   
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Individuals who test positive have specific screening and management guidelines. Increased 
screening guidelines put out by the National Comphrehensive Cancer Network are 
recommended for women who carry a mutation in BRCA1 or BRCA2. These guidelines 
include breast self exam beginning at the age of 18 and a clinical breast exam every year 
beginning at the age of 25. It is also recommended that these women receive mammograms 
and MRIs starting at the age of 25. Women who test positive can be offered prophylactic 
mastectomies to reduce their risk of breast cancer up to 97% [7]. They can also undergo a 
prophylactic bilateral salpingo-oophorectomy, at 35 to 40 years of age or after childbearing 
is completed, to reduce their risk of ovarian cancer by up to 96% [10]. If women choose not 
to have a bilateral salpingo-oophorectomy, they can undergo transvaginal ultrasounds and a 
CA-125 blood draws every six months beginning at the age of 35 or 5-10 years before the 
earliest age of ovarian cancer diagnosis in the family, but this screening has not been proven 
very effective at catching ovarian cancer early [11]. Tamoxifen can also be recommended 
for breast cancer prevention for women with estrogen receptor positive tumors [7]. 
Tamoxifen is a selective estrogen receptor modulator that is used to lower a woman’s risk to 
develop invasive and non-invasive breast cancer. It has also been shown to decrease the risk 
of contralateral breast cancer by about 50% [12].  
A negative BRCA1 or BRCA2 test result does not rule out an underlying genetic 
cause of breast cancer in a family [13]. Women with a strong family history of breast and/or 
ovarian cancer who test negative are considered to have an 'uninformative' test result. This 
means that there could be other genes involved in their family's risk that have not been 
identified [13]. Women who test negative for a known familial mutation are considered true 
negatives for a BRCA1 or BRCA2 mutation. Women with a previous unilateral breast cancer, 
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and a strong family history who are BRCA 1/2 negative, have screening guidelines on how 
to screen or prevent a contralateral breast cancer from developing.  It is unknown if certain 
BRCA negative women should undergo more screening than others. This unknown can cause 
anxiety among this cohort of women. Women with uninformative results have also been 
found to show more worry after finding out their results [14].  
 
CONTRALATERAL BREAST CANCER 
Contralateral breast cancer is the most common second primary cancer in patients 
treated for a first breast cancer, and is thought to account for about 50% of all second 
cancers in women [1]. When defining contralateral breast cancer, it is important to 
categorize according to timing of presentation of the second cancer. Synchronous 
contralateral breast cancer occurs when the second breast tumor develops at the same time 
or close to the same time as the first primary cancer. Metachronous contralateral breast 
cancer occurs when a time period of more than 3 months has elapsed since the first primary 
breast cancer [15]. Kollias et al (1999) defined metachronous breast cancer as not being 
found and treated at the time of the first primary breast cancer.  Most of the literature about 
contralateral breast cancer focuses on metachronous contralateral breast cancer, since it can 
be hard to distinguish a synchronous breast cancer from a metastases of the first primary. 
This is also the case because the incidence of primary bilateral breast cancer is low, occuring 
between 1-14% in women diagnosed with a primary invasive breast cancer [8].   
It is known that women who have been previously diagnosed with breast cancer have 
an estimated two- to six-fold higher risk of developing contralateral breast cancer at some 
point in their life over the general population’s risk to develop a primary breast cancer 
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[2,16,17,18]. This amounts to approximately 5-10% of women who have been treated for 
breast cancer getting a second primary in the opposite breast [19]. Gao et al (2003) found 
that the risk of developing contralateral brest cancer at 10-, 15-, and 20-years after the first 
primary was 6.1%, 9.1%, and 12%, respectively.  Once a woman has developed contralateral 
breast cancer her 1-, 5-, 10-, and 15-year survival rate was found to be 94%, 70%, 55%, and 
49%, respectively [20]. This same study found that survival after a contralateral breast 
cancer diagnosis was worse among the youngest women, those patients who were diagnosed 
within 5 years of their first diagnosis, poor African American women, women with either of 
their primary’s diagnosed at a later stage, those with less than 12 years of school, single 
women, and those with  major weight gain between age 18 and adulthood [20]. A different 
study looked at the survival rates of those diagnosed with contralateral breast cancer versus 
those with unilateral breast cancer. They found that if the contralateral breast cancer was 
diagnosed within 5 years of the initial primary breast cancer that the prognosis was worse 
than for those whom the contralateral breast cancer was diagnosed after five years and for 
those diagnosed with unilateral breast cancer [21].  This same study found that patients that 
had positive lymph nodes with their contralateral breast cancer had double the risk of dying 
from their breast cancer as opposed to patients who’s lymph nodes were negative and also 
that a higher stage of the contralateral breast cancer lead to a poorer prognosis [21].   
Despite the poorer prognosis after a diagnosis of contralateral breast cancer, the incidence of 
contralateral breast cancer has been declining in the United States since 1985 by about 3% 
per year [3]. The study contributes this decline to the increased use of Tamoxifen adjuvant 
therapy in patients with ER-positive breast cancer. There was no decrease in contralateral 
breast cancer in patients with ER-negative breast cancer, due to the fact that these patients 
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do not take Tamoxifen. A different study reported an increase of 150% from 1998 to 2003 in 
contralateral prophylactic mastecomy [22]. This could also contribute to the decrease of 
contralateral breast cancer by removing the unaffected breast at the same time as the 
affected breast.   
 
HBOC AND CONTRALATERAL BREAST CANCER 
Women carrying a mutation in BRCA1 or BRCA2 are also at an increased risk to 
develop a second breast cancer [16]. The risk to develop breast cancer in the opposite breast 
is up to 53%, vs 2% for the general population [8,23]. In general, BRCA1 and BRCA2 
mutation carriers have a 4-fold increase of developing contralateral breast cancer after a first 
primary breast cancer, which computes to a 4.5-fold increase in BRCA1 mutation carriers 
and a 3.4-fold increase in BRCA2 mutation carriers [2]. BRCA1 mutation carriers have a 
36.1% to 43.4% 10-15 year risk of developing contralateral breast cancer and BRCA2 
mutation carriers have a 28.5% to 34.6% 10-15 year risk [7,24]. This risk of developing 
contralateral breast cancer in BRCA1/2 mutation carriers depends mostly on age at first 
breast cancer and whether the mutation is in BRCA1 or BRCA2 [23] .  
The risk can also be changed based on whether the patient had radiation as part of 
her treatment for the first breast cancer.  Paradiso et al. (2011) found that a mutation in 
BRCA1 or BRCA2 can be found to impair DNA repair and in vitro hypersensitivity to 
radiation of BRCA-null cells. This raises a woman's risk to develop radiation complications, 
including second cancers [7].   
Metcalfe et al (2011) found that the risk to develop contralateral breast cancer in 
BRCA 1/2 mutation carriers decreases with older age of diagnosis and increases with the 
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number of first degree relatives affected with breast cancer, in a cohort of 810 women where 
a BRCA1 or BRCA2 mutation had been found in the family. In women who carry a mutation 
in BRCA1, the risk to develop contralateral breast cancer increases by 1.2 fold for each first 
degree relative diagnosed with breast cancer under the age of 50 and for women who carry a 
mutation in BRCA2 the risk increases by 1.7 fold [24]. They also found that a bilateral 
salpingo oophorectomy will reduce the risk of contralateral breast cancer in young women 
who carry a BRCA 1/2 mutation.  
It is thought that known BRCA 1/2 mutation carriers have a higher incidence of 
contralateral breast cancer because their first breast cancer is picked up at younger ages and 
therefore they have more time to develop a second breast cancer than someone diagnosed at 
an older age [16].  BRCA1 carriers are usually diagnosed with their first primary breast 
cancer at younger ages as well as being diagnosed with contralateral breast cancer at 
younger ages [23].  Malone et al. (2010) looked at BRCA1 mutation carriers relative risk of 
developing contralateral breast cancer by age of first diagnosis. They found that women 
diagnosed with a first primary breast cancer under the age of 35 had an 11-fold increase in 
developing contralateral breast cancer, women between the ages of 35-44 at the time of their 
first diagnosis had a 4-fold increase, and women between the ages of 45-54 at the first 
diagnosis had a 2.6-fold increase in contralateral breast cancer risk. Since contralateral 
breast cancer is the most common second primary cancer in patients previously diagnosed 
with breast cancer, knowing the risk factors associated with contralateral breast cancer is 
important to treating these women. 
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CONTRALATERAL BREAST CANCER RISK FACTORS: AGE AND ETHNICITY 
Certain risk factors for developing contralateral breast cancer have been studied. 
Some  factors include a strong family history of breast cancer, age of onset of first primary 
breast cancer, and if the first primary was a lobular carcinoma, which has about a 20% risk 
of being bilateral [1,8,16,17,19,23,25].  Gao et al (2003) found that being over the age of 55 
was a risk factor for developing contralateral breast cancer compared to being between the 
ages of 45 and 55 years old. They also found that being younger than 45 years of age was a 
risk factor for developing contralateral breast cancer as opposed to being between 45 and 55 
years old. It was also found that African-American women had a 20% higher risk to develop 
contralateral breast cancer over non-hispanic Caucasian women [1]. Having a significant 
family history of breast cancer and a previous unilateral breast cancer diagnosis under the 
age of 50 also increased a patient’s risk to develop contralateral breast cancer [19]. 
 
PREVIOUS PRIMARY CANCER CHARACTERISTICS 
Gao et al (2003) was the first study to find that radiation therapy used as treatment of 
the first primary breast cancer would increase the patients risk to develop contralateral breast 
cancer in a cohort of patients treated for early-stage primary breast cancer. They found that 
contralateral breast cancer risk doubled in the population that was less than 45 years old at 
primary tumor diagnosis and received radiation therapy during a 15-20 year follow up 
period [1]. One study found that the estrogen receptor status of the first primary breast 
cancer was very highly associated with estrogen receptor status of the second primary breast 
cancer [26]. Alkner et al (2011) found that receiving chemotherapy as a treatment for 
primary breast cancer was associated with a more aggressive form of contralateral breast 
10 
 
cancer. However, receiving chemotherapy does not increase the risk to get contralateral 
breast cancer [24]. Imyanitov et al. (2003) showed that premenopausal women had a higher 
level of similarity in their primary and contralateral tumor characteristics than those women 
who underwent menopause between their two diagnoses. They used this finding to suggest 
that hormonal factors influence tumor characteristics [16].  
 
LIFESTYLE 
One study found that regular alcohol intake increased the risk of metachronous 
contralateral breast cancer and this increased with longer duration of use [27]. This is 
consistent with the finding that alcohol is also a risk factor for primary breast cancer. Knight 
et al. (2009) found that smoking was not related to metachronous contralateral breast cancer.  
Li et al (2011) looked at the relationship between diabetes and the risk of developing 
contralateral breast cancer. They found that diabetic women had a 2.2 fold increase in 
developing contralateral breast cancer over women who were not diabetic and this risk was 
increased when women were diagnosed with their primary breast cancer before the age of 60 
[28]. The link between diabetes and obesity has been looked at in these studies. Li et al 
(2011) recognized that obesity is a risk factor for diabetes and breast cancer as well. A 
different study looked specifically at the risk of contralateral breast cancer in obese women. 
They found that obese postmenopausal patients that had a first primary breast cancer that 
was ER negative had an increased risk of developing contralateral breast cancer compared to 
non-obese women with ER-negative primary breast cancer [29]. They did not find an 
increased risk in pre- or postmenopausal women with an primary breast cancer that was ER 
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positive. This study also found that weight change between the primary and secondary 
tumors was not associated with increased risk of contralateral breast cancer [29]. 
 
REPRODUCTIVE RISK FACTORS 
Reproductive factors and their associated risk to develop contralateral breast cancer 
have been studied. It was found that having menarche before the age of 13 can be associated 
with a slight increase in contralateral breast cancer risk [5,30]. It has been found that having 
a full-term pregnancy can reduce a postmenopasual woman’s risk to develop contralateral 
breast cancer, although having the first pregnancy in their 30’s or 40’s actually increases a 
woman’s risk for breast cancer over a nulliparous woman [30]. Going through menopause 
has not been found to be associated with an increase in contralateral breast cancer risk [30]. 
Metcalfe et al. (20011) found that woman who were diagnosed with a primary breast cancer 
under the age of 50 and who had a bilateral salpingo-oophorectomy had a decreased risk of 
contralateral breast cancer [24].   
Figueiredo et al. (2010) looked at the association between oral contraceptive use and 
post-menopausal hormone use and the risk to develop contralateral breast cancer in carriers 
of BRCA 1/2 mutations and non-carriers. They found that the association between oral 
contraceptive use and post-menopausal hormone use and the risk of contralateral breast 
cancer did not differ between carriers and non-carriers. They also speculate that since 
carriers have a higher risk of developing contralateral breast cancer, that even a small 
increase risk from oral contraceptive use might be pertinent in the assessment of 
contralateral breast cancer risk [31]. In the study by Poynter et al. (2010), it was noted that 
there was no difference in contralateral breast cancer risk between BRCA 1/2 mutation 
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carriers and non-carriers when comparing reproductive risk factors. Imkampe et at (2011) 
found that the use of oral contraceptive pills was one of the strongest predictors of 
developing breast cancer at a young age. This study states that the use of oral contraceptive 
pills will increase a woman's breast cancer risk by inducing high breast proliferation rates, 
especillay in nulliparous women. They also found that the duration of use had no affect on 
the development of breast cancer [32]. 
 
DECREASE IN RISK 
The risk of developing contralateral breast cancer is significantly decreased if the 
woman undergoes a bilateral mastectomy at the time of the first primary and if they use 
Tamoxifen [17,18,23]. One study found that a prophylactic bilateral mastectomy can lower 
the risk of contralateral breast cancer up to 97% [7]. Poynter et al. (2010) found a lower risk 
of developing contralateral breast cancer in women who were older when they entered 
menopause, in women who had more full term births, and women who were younger at the 
time of parity.  
 
BREAST CANCER RISK ASSESSMENT MODELS 
There are several risk assessment models that assess a woman’s risk of developing 
breast cancer as well as their risk to carry a BRCA mutation. One of these risk assessment 
model’s is the BRCAPro model found in CancerGene 5.1 software. The BRCAPro risk 
assessment model is used to calculate the likelihood of identifying a mutation in BRCA1 or 
BRCA2 in an individual. The model is based on a Bayesian probability that uses a patient's 
personal and family history of breast and ovarian cancer to determine their personal risk to 
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carry a mutation. The model includes information about the patient's first and second degree 
relatives history of unilateral or contralateral breast cancer and ovarian cancer and their ages 
of diagnosis. This model also takes into account a patients unaffected relatives and their ages 
[9]. BRCAPro was developed by Parmigiani et al and has been validated in numerous 
studies [33].  The BRCAPro model is run on all of the genetic counseling patients seen at 
MD Anderson Cancer Center’s Breast Center.  
 
PREVIOUS STUDIES 
There have been previous studies evaluating women with sporadic breast cancer and 
women with  BRCA1 and BRCA2 mutations with breast cancer and their risks for developing 
a contralateral breast cancer. Kollias et al (1999) studied the risk of contralateral breast 
cancer in women previously treated for a breast cancer. Gao et al (2003) studied women 
treated for early-stage breast cancer and their risk to develop contralateral breast cancer. 
Kirova et al (2005) studied whether a woman's mutation carrier status would influence her 
risk to develop contralateral breast cancer after having breast-conserving surgery and 
treatment.   Yi et al (2009) studied the clinical features that predict contralateral breast 
cancer that may help a patient with unilateral breast cancer and her decision to undergo a 
contralateral prophylactic mastectomy. Graeser et al (2009) studied the risk for contralateral 
breast cancer in BRCA1 and BRCA2 mutation carriers. To our knowledge, there have been 
no studies specifically on uninformative BRCA negative women who have familial breast 
cancer and their risk to develop contralateral breast cancer.  
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OBJECTIVE 
 The objective of this study is to evaluate and determine risk factors for the 
development of contralateral breast cancer among women who test negative for BRCA1 or 
BRCA2 and who have high BRCAPro (>10%) scores. Our cohort is comprised of women 
who have been previously diagnosed with invasive breast cancer and who tested negative for 
a mutation in the BRCA1 and BRCA2 genes. We then study the time to contralateral breast 
cancer development and evaluate which predictors associate with increased breast cancer 
risk. We studied women with a BRCAPro score of greater than 10% because this has been 
proven previously to be associated with higher BRCA1/BRCA2 mutation rates [34], and so 
this groups of women are at a higher probability of having inherited susceptibility to breast 
cancer and of developing another cancer. This study can help clinician’s assess a BRCA 
negative woman’s risks to develop a contralateral breast cancer and to determine the correct 
screening protocol for these patients. Some patients with high BRCAPro scores may be 
sufficiently anxious about their risks for developing a contralateral beast cancer that they 
consider prophylactic mastectomy even in the absence of a known mutation. Therefore, it is 
of interested to evaluate specific risk factors for contralateral breast cancers. 
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MATERIALS AND METHODS 
 
STUDY DESIGN 
 A retrospective chart review was performed on a select cohort of women in an MD 
Anderson database. These women had a previous diagnosis of invasive breast cancer and 
had tested negative for a mutation in the BRCA1 or BRCA2 genes. Women included in the 
study were under the age of 50 at their first diagnosis and had a BRCAPro score of greater 
than 10%. The specific aim of this study was to determine predictors of contralateral breast 
cancer and the incidence of contralateral breast cancer in BRCA negative women with a 
BRCAPro >10% who had an invasive breast cancer diagnosed under the age of 50. The 
electronic medical records of the women at MD Anderson were reviewed and data was 
entered into a database. Some of the factors studied included: family history of breast and/or 
ovarian cancer, primary tumor characteristics, and reproductive factors. The factors were 
then analyzed to determine what predictors, if any, predicted an increased risk for 
developing a contralateral breast cance. The study also looked at the incidence of 
contralateral breast cancer in this population. The hypothesis of the study was that there are 
many predictors associated with contralateral breast cancer and an associated incidence for 
women with a previous unilateral breast cancer who have tested negative for a BRCA 
mutation and have a BRCAPro greater than 10%. 
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STUDY APPROVAL 
 The study received approval from the University of Texas Health Science Center of 
Houston- Graduate School of Biomedical Sciences on July 25, 2011. It also received 
approval from MD Anderson on October 6, 2011. 
 
STUDY POPULATION 
 The study population contained 572 women who had an invasive breast cancer 
diagnosed under the age of 50, had tested negative for a BRCA mutation, and had a 
BRCAPro score of greater than 10%. The women were tested between 1997 and August, 31, 
2011. A total of 97 women in the population developed contralateral breast cancer. 
 
ASCERTAINMENT 
  The study population was obtained from a MD Anderson database. The original 
cohort consisted of 1,641 patients who met the criteria of having an invasive breast cancer 
diagnosed under the age of 50 and had tested negative for a BRCA mutation. Of the 1,641 
patients, 1,069 were excluded because they did not meet the study criteria. The exclusion 
criteria included women diagnosed with DCIS, women diagnosed over the age of 50 with 
their first primary tumor, women with a BRCAPro score of less than 10%, men, women 
with a true negative result, and women with a different hereditary condition. 
 
DATA COLLECTION 
 Data was reviewed and collected from November 2011 through February 2012. The 
data was then entered into a database and the information obtained is displayed in Table 1. 
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Table 1: Variables Obtained from Electronic Medical Record 
General Information 
Ethnicity 
Age at Diagnosis of first invasive breast cancer 
BRCAPro number 
Smoker/Smoking Length 
Alcohol Use 
Ashkenazi Jewish ancestry 
BMI 
Reproductive Risk Factors 
Age at menarche 
Ever Parous/Age at first full term pregnancy 
Menopause/Age at Menopause 
Hormone replacement use/Length 
Oral Contraceptive Use/Length 
Risk Reducing Surgery 
Prophylactic mastectomy 
Bilateral Salpingo-oophorectomy 
Total Abdominal Hysterectomy 
Age at BSO/TAH 
Genetic Testing Type 
Sequencing 
BART 
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Ashkenazi Jewish panel 
Family History Information 
Number of First Degree Relatives with Breast Cancer 
Number of Second Degree Relatives with Breast Cancer 
Number of First Degree Relatives with Ovarian Cancer 
Number of Second Degree Relatives with Ovarian Cancer 
First Primary Tumor Pathology Information 
Tumor receptor status 
Her2/neu Status 
Grade 
Lymphovascular Invasion 
Pathology of Tumor 
Previous Biopsy/Previous Biopsy Number 
Tumor Size 
Treatment 
Radiation Exposure 
Chemotherapy 
Tamoxifen Use/Length 
Contralateral Tumor Pathology Information 
Pathology of Tumor 
Tumor Receptor Status 
Grade 
Lymphovascular Invasion 
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Synchronous/Metachronous diagnosis 
Tumor Size 
 
STATISTICAL ANALYSIS 
 Statistical analysis was performed on the data to determine if any trends were present 
that would help identify predictors of contralateral breast cancer in this population. 
Microsoft Office Excel 2010, Microsoft Office Access 2010, and STATA 12.0 were all used 
to study this population’s data. Descriptive analysis of the data was used to describe the 
cohort. The frequencies of each variable as well as the mean and range of the variables was 
determined to help summarize the cohort. 
 Cox Proportional Hazard Model was used to assess the relationship between the time 
to develop contralateral breast cancer to the covariables used in the study. The Cox model 
analyzes time to recurrence of breast cancer allowing for incomplete information about the 
time to breast cancer development caused by censoring. Censoring is when the patient either 
did not develop contralateral breast cancer, they were lost to follow-up or they passed away 
before they developed contralateral breast cancer, so it is unknown when they would have 
developed contralateral breast cancer. In our Cox Proportional Hazard Model, we set the 
time variable as follow-up time after primary, time to death after primary or time to develop 
contralateral breast cancer after primary. Our failure event was whether the patient 
developed contralateral breast cancer or not. Univariable Cox Proportional Hazard Model 
was performed on each variable to determine which covariables could be of statistical 
interest. We used a p-value of 0.2 to screen for potentially interesting covariates to include 
in the multivariable analysis. Kaplan-Meier curves represent graphical presentation for each 
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covariate identified in the univariable Cox model as potentially interesting. Stepwise 
multivariable Cox Proportional Hazard Model was then performed on the selected covariates 
to arrive at a final parsimonious multivariable model consisting of only significant 
covariates, defining statistically significant variables with different thresholds, i.e. as having 
a p-value of less than 0.05 or less than 0.1. We then performed recursive partitioning using a 
decision tree that represents an optimal way of combining the significant covariates to 
classify the women into risk groups represented by the different times they develop 
contralateral breast cancer. A Kaplan-Meier curve was plotted for each of the five terminal 
nodes. These five nodes were then grouped into three different risk groups and a new 
Kaplan-Meier curve was made on these final three groups. The three groups were defined as 
being low-risk, medium-risk or high-risk.  
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RESULTS 
 
The cohort for our study is described in the flow chart in Figure 1. We began with 
1,641 women who had a previous unilateral invasive breast cancer, had tested negative for a 
mutation in the BRCA1 or BRCA2 genes, and were diagnosed with a primary invasive breast 
cancer under the age of 50 years. We then evaluated the BRCAPro risk assessment 
probability for each woman in the cohort. This excluded 1,044 woman from the cohort 
based on the exclusion criteria of: a BRCAPro probability of less than 10%, women who 
had DCIS as their first primary diagnosis, women with a true negative result, women with a 
different hereditary condition, and men. After reviewing the 597 woman left in the cohort, 
25 more women were excluded because they were true negatives or they had a different 
hereditary condition, i.e. Li Fraumeni syndrome or Cowden syndrome, leaving a final cohort 
of 572. This included 475 women with unilateral breast cancer and 97 women who 
developed contralateral breast cancer (CBC). 
 
Figure 1: Flowchart of Study Cohort 
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DEMOGRAPHIC AND LIFESTYLE  
Follow-Up Time 
The average follow-up time was 7.11 years. Follow-up time included time to develop 
contralateral breast cancer, time to death, and time at last follow-up; all calculated from the 
time of the primary diagnosis in years. The range of follow-up time was 0.1 years to 46 
years. The standard deviation was 7.36. The final cohort had 51 women who were deceased 
at the closing of the data collection. 521 women were still living at the end of data 
collection. 
Ethnicity 
There were 413 Non-Hispanic White women in the population, which is 
approximately 72% of the cohort. There were 84 Hispanic women (15%), 51 African-
American women (9%), 13 Asian women (2%), and 11 (2%) women of ‘Other’ ethnicity.  
Age at Primary Diagnosis 
The average age at the first primary diagnosis was 41.05 years with the minimum 
age being 22 years and the maximum age being 50 years old. The standard deviation was 
6.22. 
BRCAPro Risk Assessment Number 
The average BRCAPro risk assessment probability of the cohort was 23.23%. This 
ranged from 10%-100% over the entire cohort. The standard deviation was 18.58. 
Ashkenazi Jewish 
There were 502 women who were not of Ashkenazi Jewish ancestry (87.76%) and 
70 (12.24%) women who were Ashkenazi Jewish. 
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Smoker/Smoking Length 
There were 347 (60.66%) women who reported no history of smoking and 206 
(36.01%) women who had a history of smoking. There were 19 women who did not have 
information regarding their smoking habits. The average number of years women in the 
cohort smoked was 15.70 years with a range of 1 year to 50 years. There were 164 women 
who had information regarding how long they smoked cigarettes. The standard deviation of 
smoking length was 10.95. 
Alcohol Use 
There were 203 (35.49%) women who had no history of ever drinking alcohol and 
350 (61.19%) women who drank alcohol in some amount. There were 19 women who did 
not have information regarding ever drinking alcohol. 
Body Mass Index (BMI) 
The average body mass index (BMI) for the cohort at the initial diagnosis was 27.21 
with a range of 17 to 61. The standard deviation was 6.41. There was information regarding 
BMI for 521 women in the cohort. 
Ovarian Cancer 
There were 9 (1.57%) women in the cohort who developed ovarian cancer and 563 
(98.43%) women who did not get ovarian cancer. 
 
The demographic and lifestyle covariables’ categorical data are summarized in Table 
2 and the discrete data are summarized in Table 3. The ethnicity of the population is 
summarized in Figure 2. 
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Table 2: Categorical Data of Demographic and Lifestyle Covariables 
Variable Observations Mean Std. Dev. Min Max 
Follow-Up Time 572 7.11 7.36 0 46 
Diagnosis Age 572 41.05 6.22 22 50 
BRCAPro 572 23.23 18.58 10 100 
Smoking Length 164 15.70 10.95 1 50 
BMI 521 27.21 6.41 17 61 
  
Table 3: Discrete Data of Demographic and Lifestyle Covariables 
Variable No Yes Unknown 
Ashkenazi Jewish 502 (87.76%) 70 (12.24%) 0 
Smoker 347 (60.66%) 206 (36.01%) 19 (3.32%) 
Alcohol Use 203 (35.49%) 350 (61.19%) 19 (3.32%) 
Ovarian Cancer 563 (98.43%) 9 (1.57%) 0 
 
Figure 2: Ethnicity of the Cohort 
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REPRODUCTIVE RISK FACTORS 
Age at Menarche 
The average age of menarche for the cohort was 12.45 years old with a range of 8 
years old to 18 years old. Of note, there are 40 women who did not have information about 
the age of menarche. The standard deviation was 1.49. 
Parity/Age at First Full Term Birth 
There were 103 (18.01%) nulliparous women and 469 (81.99%) parous women. The 
average age at parity was 25.82 years old with a range of 14 years old to 43 years old. There 
were 2 women who did not have information regarding the age at parity. The standard 
deviation for age at the first birth was 5.51. 
Experienced Menopause/Age at Menopause 
There were 250 (43.71%) women who had not gone through menopause and 283 
(49.48%) who had experienced menopause. There were 39 women who did not have 
information in their medical record regarding menopausal status. The average age at 
menopause was 43.25 years with a range from 27 to 58 years of age. There was information 
regarding the average age of menopause for 263 women in the cohort. The standard 
deviation for the age at menopause was 5.65. 
Hormone Replacement Use/Length of Use of Hormone Replacement 
There were 425 (74.30%) women who had never used hormonal replacement and 85 
(14.86%) women who had used hormones. There were 62 (10.84%) women who did not 
have information regarding hormonal use in their medical records. The average length of use 
of hormone replacement was 3.30 years with a range from 0.08 years to 18 years. There 
were 74 women who had information regarding how many years they were on hormone 
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replacement therapy. The standard deviation of the length of hormone replacement use was 
4.21 years. 
Oral Contraceptive Pills Use/Length of Use of Oral Contraceptive Pills 
There were 416 women who had information regarding how long they used oral 
contraceptive pills. There were 93 (16.26%) women who never used oral contraceptive pills 
and 431 (75.35%) women who had used oral contraceptive pills for some length of time. 
The average length of use of oral contraceptive pills was 8.62 years with a range from 0.02 
years to 35 years. The standard deviation of the length of oral contraceptive pill use was 
6.87. 
The reproductive risk factors’ quantitative data is summarized in Table 4 and the 
discrete data is summarized in Table 5. 
 
Table 4: Reproductive Risk Factors’ Quantitative Data 
Variable Observations Mean Std. Dev. Min Max 
Age at Menarche 532 12.45 1.49 8 18 
Age at First Birth 467 25.82 5.51 14 43 
Age at Menopause 263 43.25 5.65 27 58 
Hormone Use Length 74 3.30 4.21 0.08 18 
OCP Use Length 416 8.62 6.87 0.02 35 
 
 
 
 
27 
 
Table 5: Reproductive Risk Factors’ Discrete Data 
Variable No Yes Unknown 
Ever Parous 103 (18.01%) 469 (81.99%) 0 
Menopause 250 (43.71%) 283 (49.48%) 39 (6.82%) 
Hormone Use 425 (74.30%) 85 (14.86%) 62 (10.84%) 
OCP Use 93 (16.26%) 431 (75.35%) 48 (8.39%) 
 
RISK REDUCING SURGERY RISK FACTORS 
Prophylactic Mastectomy 
There were 445 (79.79%) women who did not undergo a prophylactic mastectomy 
and 124 (20.21%) women who did undergo a prophylactic mastectomy. One woman 
developed contralateral breast cancer after having a prophylactic mastectomy. 
Bilateral Salpingo-Oophorectomy/Age at Bilateral Salpingo-Oophorectomy 
In this cohort, there were 380 (66.43%) women did not have a bilateral salpingo-
oophorectomy (BSO) and 113 (19.76%) who had a bilateral salpingo-oophorectomy. There 
were 79 (13.81%) women who did not have this information in their medical records. The 
average age of bilateral salpingo-oophorectomy in this cohort was 43.21 years old with a 
range of 27 years old to 70 years old. The standard deviation of the age at the time of a 
bilateral salpingo-oophorectomy was 7.46. 
Total Abdominal Hysterectomy/Age at Total Abdominal Hysterectomy 
There were 351 (61.36%) women who have not had a total abdominal hysterectomy 
(TAH) and 143 (25%) women who have. There were 78 (13.64%) women who did not have 
this information in their medical records. The average age of undergoing a total abdominal 
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hysterectomy was 41.78 years old with a range of 23 years old to 70 years old. There were 
138 women in our cohort who underwent a TAH and had information regarding the age at 
the time of the procedure. The standard deviation of the age at the time of the total 
abdominal hysterectomy was 8.03. 
 
The risk reducing surgery covariables’ quantitative data are summarized in Table 6 and the 
discrete data are summarized in Table 7. 
 
Table 6: Risk Reducing Surgery Quantitative Data 
Variable Observations Mean Std. Dev. Min Max 
Age at BSO 108 43.21 7.46 27 70 
Age at TAH 138 41.78 8.03 23 70 
 
Table 7: Risk Reducing Surgery Discrete Data 
Variable No Yes Unknown 
Prophylactic Mastectomy 445 (79.79%) 124 (20.21%) 0 
BSO 380 (66.43%) 113 (19.76%) 79 (13.81%) 
TAH 431 (75.35%) 141 (24.65%) 78 (13.64%) 
 
FAMILY HISTORY 
Number of First Degree Relatives with Breast Cancer 
There were 362 (63.29%) women who did not have a first degree relative with breast 
cancer and 210 (36.71%) women who had at least one first degree relative with breast 
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cancer. Of the 210 women, 178 (31.12%) women had one first degree relative affected with 
breast cancer. 29 (5.07%) women had two first degree relatives affected with breast cancer. 
Two women (0.35%) had three first degree relatives affected with breast cancer and one 
woman (0.17%) had five first degree relatives affected with breast cancer. 
Number of Second Degree Relatives with Breast Cancer 
There were 223 (38.99%) women who did not have a second degree relative with 
breast cancer and 349 (61.01%) women who had a second degree relative with breast 
cancer. Of the 349 women, 199 (34.79%) had one second degree relative with breast cancer. 
91 (15.91%) women had two second degree relatives affected with breast cancer. 41 
(7.17%) women had three second degree relatives affected. 10 (1.75%) had four second 
degree relatives affected. Five (0.87%) had five second degree relatives affected. Two 
(0.35%) had six second degree relatives affected and one (0.17%) woman had eleven second 
degree relatives affected with breast cancer. 
Number of First Degree Relatives with Ovarian Cancer 
There were 547 (95.63%) women who did not have a first degree relative with 
ovarian cancer and 25 (4.37%) women who had one first degree relative with ovarian 
cancer. 
Number of Second Degree Relatives with Ovarian Cancer 
There were 467 (81.64%) women who did not have a second degree relative with 
ovarian cancer and 105 (18.36%) women who had at least one second degree relative with 
ovarian cancer. In the 105 women, 97 (16.96%) women had one second degree relative with 
ovarian cancer, six (1.05%) had two relatives affected, one (0.17%) had three affected 
relatives, and one (0.17%) had five affected relatives with ovarian cancer. 
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The family history data is summarized in Table 8. The number of first degree 
relatives affected with breast cancer is summarized in Table 9. The number of second degree 
relatives affected with breast cancer is summarized in Table 10. The number of first degree 
relatives affected with ovarian cancer is summarized in Table 11. The number of second 
degree relatives affected with ovarian cancer is summarized in Table 12. 
 
Table 8: Family History of Having or Not Having Affected Relatives 
Variable No Yes 
FDR with Breast Cancer 362 (63.29%) 210 (36.71%) 
SDR with Breast Cancer 223 (38.99%) 349 (61.01%) 
FDR with Ovarian Cancer 547 (95.63%) 25 (4.37%) 
SDR with Ovarian Cancer 467 (81.64%) 105 (18.36%) 
 
Table 9: Number of First Degree Relatives Affected with Breast Cancer 
Number of Relatives Affected Number of Patients in Cohort 
0 362 (63.29%) 
1 178 (31.12%) 
2 29 (5.07%) 
3 2 (0.35%) 
5 1 (0.17%) 
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Table 10: Number of Second Degree Relatives Affected with Breast Cancer 
Number of Relatives Affected Number of Patients in Cohort 
0 223 (38.99%) 
1 199 (34.79%) 
2 91 (15.91%) 
3 41 (7.17%) 
4 10 (1.75%) 
5 5 (0.87%) 
6 2 (0.35%) 
11 1 (0.17%) 
 
Table 11: Number of First Degree Relatives Affected with Ovarian Cancer 
Number of Relatives Affected Number of Patients in Cohort 
0 547 (95.63%) 
1 25 (4.37%) 
 
Table 12: Number of Second Degree Relatives Affected with Ovarian Cancer 
Number of Relatives Affected Number of Patients in Cohort 
0 467 (81.64%) 
1 97 (16.96%) 
2 6 (1.05%) 
3 1 (0.17%) 
5 1 (0.17%) 
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PRIMARY TUMOR CHARACTERISTICS 
Estrogen Receptor Status 
There were 183 (32%) women who had a negative ER status. There were 386 
women who had a positive ER status. There were 3 (0.52%) women who did not have 
information about ER status of their primary tumor. 
Progesterone Receptor Status 
There were 251 (43.88%) women who had a negative PR status and 318 (55.60%) 
women who had a positive PR status. There were 3 (0.52%) women who did not have 
information about PR status in their medical records. 
Her2/neu Status 
There were 477 (83.40%) women who had a negative Her2/neu status. There were 
92 (16.08%) women who had positive Her2/neu status. There were 3 (0.52%) women who 
did not have Her2/neu status of the primary tumor in their medical records. 
Pathology of Tumor 
There were 34 (5.94%) women who had invasive lobular carcinoma. There were 445 
(77.80%) women who had invasive ductal carcinoma. There were 8 (1.40%) women who 
had invasive tubular carcinoma. There were 9 (1.57%) women who had inflammatory breast 
cancer and 32 (5.59%) women who had mixed ductal carcinoma. There were 11 (1.92%) 
women who had an ‘other’ pathology subtype of their tumor. There were 33 (5.78%) women 
who did not have any information regarding the pathology of their primary tumor. 
Previous Biopsy/Previous Biopsy Number 
There were 485 (84.79%) women who had never had a previous biopsy and 84 
(14.69%) women who had previous biopsies. There were 3 (0.52%) women who did not 
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have information regarding previous biopsies. The average previous biopsy number was 
0.63 with a range of 0 to 10. The standard deviation of the previous biopsy number was 
1.32. 
Tumor Size 
The average tumor size for the primary tumor was 2.56cm and the range was 0.07cm 
to 12cm. There was information regarding tumor size of the primary tumor for 504 patients. 
The standard deviation of the size of the primary tumor was 1.92. 
Grade of Tumor 
There were 61 women who had a grade 1 primary tumor, which is 12.35% of the 
patient population. There were 209 women who had a grade 2 primary breast cancer tumor, 
which was 42.31% of the study population. There were 224 women who had a grade 3 
primary cancer tumor, which was 45.34% of the patient population. The majority of our 
study cohort had a high grade primary breast cancer tumor. 
Lymphovascular Invasion 
There were 339 (59.58%) women who did not have lymphovascular invasion during 
their first primary and 230 (40.42%) women who had positive lymphovascular invasion 
during their first primary diagnosis treatment. 
 
The primary tumor characteristics’ quantitative data is summarized in Table 13. The 
primary tumor characteristics’ discrete data is summarized in Table 14. The grade of the 
primary tumor is summarized in Figure 3. The pathology subtype of the primary tumor is 
summarized in Table 15. 
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Table 13: Primary Tumor Characteristics’ Quantitative Data 
Variable Observations Mean Std. Dev. Min Max 
Prev. Biopsy Number 263 0.63 1.32 0 10 
Tumor Size 504 2.56 1.92 0.07 12 
 
Table 14: Primary Tumor Characteristics’ Discrete Data 
Variable Negative Positive Missing 
ER Status 183 (32%) 386 (67.48%) 3 (0.52%) 
PR Status 251 (43.88%) 318 (55.60%) 3 (0.52%) 
Her2/neu Status 477 (83.40%) 92 (16.08%) 3 (0.52%) 
Previous Biopsy  485 (84.79%) 84 (14.69%) 3 (0.52%) 
Lymphovascular Invasion 339 230 0 
 
Figure 3: Grade of Primary Tumor 
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Table 15: Pathology Subtype of Primary Tumor 
Pathology Subtype Number of Patients with Subtype 
Invasive Lobular Carcinoma 34 (5.94%) 
Invasive Ductal Carcinoma 445 (77.80%) 
Invasive Tubular Carcinoma 8 (1.40%) 
Inflammatory 9 (1.57%) 
Mixed Ductal Carcinoma 32 (5.59%) 
Other Subtype 11 (1.92%) 
Missing 33 (5.78%) 
 
TREATMENT 
Radiation Therapy 
There were 215 (37.59%) women who were not treated with radiation during their 
first primary diagnosis treatment and 354 (61.89%) women who received radiation 
treatment. There were 3 (0.52%) women who did not have this information. 
Chemotherapy 
There were 105 (18.36%) women who did not receive chemotherapy as part of their 
treatment and 464 (81.12%) women who had chemotherapy. There were 3 (0.52%) women 
missing this information. 
Tamoxifen Use/Tamoxifen Length of Use 
There were 268 (46.85%) women who did not use Tamoxifen and 304 (53.15%) 
women who did use Tamoxifen. The average length of use of Tamoxifen was 3.24 years 
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with a range of 0.04 years to 10 years. There was information regarding length of Tamoxifen 
use for 194 patients. The standard deviation of the length of use of Tamoxifen was 2.03. 
 
The treatment covariables’ quantitative variables are summarized in Table 16 and the 
discrete data is summarized in Table 17. 
 
Table 16: Treatment Quantitative Data 
Variable Observations Mean Std. Dev. Min Max P-Value 
Tamoxifen Use Length  194 3.24 2.03 0.04 10 0.99 
 
Table 17: Treatment Discrete Data 
Variable No Yes Missing 
Radiation Therapy 215 (37.59%) 354 (61.89%) 3 (0.52%) 
Chemotherapy 105 (18.36%) 464 (81.12%) 3 (0.52%) 
Tamoxifen Use 268 (46.85%) 304 (53.15%) 0 
 
CONTRALATERAL BREAST CANCER COVARIABLES 
Synchronous vs. Metachronous Contralateral Breast Cancer 
There were 27 (27.84%) women who had their contralateral breast cancer diagnosed 
at the same time or within 3 months of their primary breast cancer diagnosis. There were 64 
(65.98%) women who had their contralateral breast cancer diagnosed at least 3 months after 
their primary breast cancer diagnosis. There were 6 (6.19%) women missing this 
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information. The average time to develop contralateral breast cancer in our cohort was 9.40 
years and the median time to develop contralateral breast cancer was 24.5 years. 
Age at Contralateral Breast Cancer 
The average age of the women at the diagnosis of contralateral breast cancer was 
50.57 years with a range of 33 years to 78 years. The standard deviation was 9.27. 
Body Mass Index at Time of Contralateral Breast Cancer 
The average BMI at the time of contralateral breast cancer diagnosis was 29.05 with 
a range of 19 to 44. There was only information on BMI at contralateral breast cancer for 61 
women. The standard deviation was 6.05. 
Pathology of Contralateral Tumor 
There were 7 (7.22%) women who had invasive lobular carcinoma and 58 (59.79%) 
women who had invasive ductal carcinoma. There were 11 (11.34%) women who had DCIS 
as their contralateral breast cancer diagnosis. There were 7 (7.22%) women who had mixed 
ductal carcinoma and 8 (8.79%) women who had an ‘other’ subtype. There were 6 (6.19%) 
women who did not have this information. 
Estrogen Receptor Status of Contralateral Tumor 
There were 31 (31.96%) women who had a negative ER tumor status or who had 
missing ER status data. There were 60 (61.86%) women who had a positive ER status in 
their contralateral breast cancer tumor. There were 6 (6.19%) women who did not have this 
information. 
Progesterone Receptor Status of Contralateral Tumor 
There were 40 (41.24%) women who had a negative PR status of their contralateral 
breast cancer tumor or who had missing PR tumor status information. There were 51 
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(52.58%) women who had a positive progesterone receptor status of their contralateral 
breast cancer tumor. There were 6 (6.19%) women missing this information. 
Her2/neu Status of Contralateral Tumor 
There were 83 (85.87%) women who had a negative Her2/neu tumor status or were 
missing this information. There were 8 (8.25%) women who had a positive Her2/neu 
contralateral breast cancer tumor. There were 6 (6.19%) women who did not have this 
information. 
Size of Contralateral Tumor 
The average size of the contralateral tumor was 1.94cm with the range being 0.1cm 
to 15cm. There was information regarding the size of the contralateral tumor for 82 tumors. 
The standard deviation was 1.93.  
Grade of Contralateral Breast Cancer Tumor 
There were 12 women who had a grade 1 contralateral breast cancer tumor, which 
was 12.37% of the contralateral tumors. There were 40 women who had a grade 2 
contralateral breast cancer tumor, which was 41.24% of the contralateral tumors. There were 
28 women who had a grade 3 contralateral breast cancer tumor, which was 28.87% of the 
contralateral tumors. There were 17 contralateral breast cancer tumors that did not have 
information regarding the grade of the tumor, which was about 17.53% of the contralateral 
tumors.  
Lymphovascular Invasion  
There were 70 (72.16%) women who did not have lymphovascular invasion and 21 
(21.65%) women who had lymphovascular invasion. There were 6 (6.19%) women who did 
not have this information. 
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The contralateral breast cancer characteristics quantitative data is summarized in 
Table 18 and the discrete data is summarized in Table 19. The grade of the contralateral 
tumor is summarized in Figure 4. The pathology of the contralateral breast cancer tumor is 
summarized in Table 20. Whether the contralateral breast cancer was synchronous or 
metachronous with the primary breast cancer is summarized in Figure 5. 
 
Table 18: Contralateral Breast Cancer Quantitative Data 
Variable Observations Mean Std. Dev. Min Max 
Age at CBC 97 50.57 9.24 33 78 
BMI at CBC 61 29.05 6.05 19 44 
Tumor Size of CBC 82 1.94 1.93 0.1 15 
 
Table 19: Contralateral Breast Cancer Discrete Data 
Variable No/Negative Yes/Positive Missing 
Lymphovascular Invasion of CBC 70 (72.16%) 21 (21.65%) 6 (6.19%) 
ER Status 31 (31.96%) 60 (61.85%) 6 (6.19%) 
PR Status 40 (41.24%) 51 (52.58%) 6 (6.19%) 
Her2/neu Status 83 (85.57%) 8 (8.24%) 6 (6.19%) 
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Figure 4: Grade of Contralateral Breast Cancer Tumor 
 
 
Table 20: Contralateral Breast Cancer Tumor Pathology Subtype 
Pathology Subtype of CBC Frequency Percentage 
Lobular 7 7.22% 
Ductal 58 59.79% 
DCIS 11 11.34% 
Mixed Ductal 7 7.22% 
Other 8 8.24% 
Missing 6 6.19% 
 
Figure 5: Synchronous vs. Metachronous Contralateral Breast Cancer 
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MOLECULAR GENETIC TESTING SUBTYPE 
565 of the women received full sequencing of both the BRCA1 and BRCA2 genes. 35 
women received the Ashkenazi Jewish panel test. In some cases but not all, the women who 
tested negative on the Ashkenazi Jewish panel were then refluxed to full sequencing. 205 
women received BART testing after being negative by full sequencing. BART testing looks 
for large rearrangements and large duplications/deletions that sequencing is unable to detect. 
This is summarized in Table 21. 
 
Table 21: Molecular Genetic Testing Subtype 
Test Type Count 
Sequencing 565 (70.19%) 
Ashkenazi Jewish Panel 35 (4.35%) 
BART 205 (25.47%) 
Total 805 
 
 
UNIVARIABLE ANALYSIS 
Univariable Cox Proportional Hazard Model was performed on each covariate with 
time to contralateral breast cancer as the response variable. We used a p-value of <0.2 to 
determine whether the covariate was of potential interest. The p-values that are in bold in the 
following tables were considered potentially interesting with a p-value less than 0.2. 
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DEMOGRAPHIC AND LIFESTYLE COVARIABLES 
Ethnicity 
The ethnicity of the cohort had a hazard ratio of 1.05 with a p-value of 0.72 (95% CI: 
0.82-1.34) which was not statistically significant. 
Age at Primary Diagnosis 
The age at primary breast cancer diagnosis had a hazard ratio of 1.04 with a 
statistically significant p-value of 0.019 (95% CI: 1.01-1.08).  
BRCAPro Risk Assessment Number 
The BRCAPro risk assessment number of the patient cohort had a hazard ratio of 
1.00 and was not statistically significant with a p-value of 0.46.  
Ashkenazi Jewish 
If the woman was of Ashkenazi Jewish ancestry, the hazard ratio was 0.99 with a p-
value of 0.98, which was not statistically significant (95% CI: 0.58-1.71).  
Smoker/Smoking Length 
If a woman ever smoked, the hazard ratio was 0.95 with a non-statistically 
significant p-value of 0.83 (95% CI: 0.62-1.46). The length of time a woman smoked had a 
hazard ratio of 1.00 and a p-value of 0.97, which was not statistically significant (95% CI: 
0.96-1.04).  
Alcohol Use 
If the woman ever drank alcohol, the hazard ratio was 0.94 with a non-statistically 
significant p-value of 0.78 (95% CI: 0.62-1.43).  
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Body Mass Index (BMI) 
The body mass index at the primary breast cancer had a hazard ratio 1.02 with a non-
statistically significant p-value of 0.24 (95% CI: 0.98-1.06).  
Ovarian Cancer 
If the woman had been diagnosed with ovarian cancer, the hazard ratio was 0.32 with 
a non-statistically significant p-value of 0.25 (95% CI: 0.04-2.28).  
 
Table 22: Demographic and Lifestyle Risk Factors Univariable Cox Proportional Hazard 
Model 
Variable Hazard Ratio P-Value Confidence Interval (95%) 
Ethnicity 1.05 0.72 0.82-1.34 
Diagnosis Age 1.04 <0.02 1.01-1.08 
BRCAPro 1.00 0.46 0.99-1.01 
Ashkenazi Jewish 0.99 0.98 0.58-1.71 
Smoker 0.95 0.83 0.62-1.46 
Smoking Length 1.00 0.97 0.96-1.04 
Alcohol Use 0.94 0.78 0.62-1.43 
BMI 1.02 0.24 0.98-1.06 
Ovarian Cancer 0.32 0.25 0.04-2.28 
 
 
 
 
44 
 
REPRODUCTIVE RISK FACTORS 
Age at Menarche 
The age of menarche had a hazard ratio of 1.04 and a p-value of 0.61, which was not 
statistically significant (95% CI: 0.89-1.21). 
Parity/Age at First Full Term Birth 
If the women had ever had a live birth, the hazard ratio was 0.79 and was not 
statistically significant with a p-value of 0.39 (95% CI: 0.47-1.34). The age of the woman at 
their first live birth had a hazard ratio of 1.03 and a statistically interesting p-value of 0.17 
(95% CI: 0.99-1.08). 
Experienced Menopause/Age at Menopause 
If the woman had gone through menopause, the hazard ratio was 0.76 with a non-
statistically significant p-value of 0.30 (95% CI: 0.46-1.27). The age the woman was at the 
time of menopause had a hazard ratio of 1.03 and a p-value of 0.073, which was statistically 
interesting (95% CI: 1.00-1.08). 
Hormone Replacement Use/Length of Use of Hormone Replacement 
If the woman ever used hormone replacement therapy, the hazard ratio was 1.05 with 
a non-statistically significant p-value of 0.87 (95% CI: 0.62-1.78). The length of use of 
hormone replacement therapy had a hazard ratio of 0.96 and a p-value of 0.64, which was 
not statistically significant (95% CI: 0.83-1.12).  
Oral Contraceptive Pills Use/Length of Use of Oral Contraceptive Pills 
If the woman ever used oral contraceptive pills, the hazard ratio was 0.65 with a 
statistically significant p-value of 0.078 (95% CI: 0.40-1.05). The length of use of oral 
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contraceptive pills had a hazard ratio of 1.01 with a p-value of 0.46, which was not 
statistically significant (95% CI: 0.98-1.05).  
 
Table 23: Reproductive Risk Factors Univariable Cox Proportional Hazard Model 
Variable Hazard Ratio P-Value Confidence Interval (95%) 
Age at Menarche 1.04 0.61 0.89-1.22 
Ever Parous 0.79 0.39 0.47-1.34 
Age at First Birth 1.03 0.17 0.99-1.08 
Menopause 0.76 0.30 0.46-1.27 
Age at Menopause 1.04 0.07 1.00-1.08 
Hormone Use 1.05 0.87 0.62-1.78 
Hormone Use Length 0.96 0.64 0.83-1.12 
OCP Use 0.65 0.08 0.40-1.05 
OCP Use Length 1.01 0.46 0.98-1.05 
 
 
RISK REDUCING SURGERY RISK FACTORS 
Prophylactic Mastectomy 
If the woman had a prophylactic mastectomy, the hazard ratio was 0.05 with a p-
value of 0.004 (95% CI: 0.01-0.38), which was statistically significant. 
Bilateral Salpingo-Oophorectomy/Age at Bilateral Salpingo-Oophorectomy 
If the woman had a bilateral salpingo-oophorectomy, the hazard ratio was 0.79 and 
the p-value was 0.36, which was not statistically significant (95% CI: 0.47-1.32). The age at 
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which the woman had her bilateral salpingo-oophorectomy had a hazard ratio of 0.99 and a 
non-statistically significant p-value of 0.82 (95% CI: 0.95-1.04). 
Total Abdominal Hysterectomy/Age at Total Abdominal Hysterectomy 
If the woman had a total abdominal hysterectomy, the hazard ratio was 0.65 with a 
statistically interesting p-value of 0.084 (95% CI: 0.40-1.06). The age at which a woman 
received her total abdominal hysterectomy had a hazard ratio of 0.98 and a non-statistically 
significant p-value 0.35 (95% CI: 0.94-1.02). 
 
Table 24: Risk Reducing Surgery Univariable Cox Proportional Hazard Model 
Variable Hazard Ratio P-Value Confidence Interval (95%) 
Prophylactic Mastectomy 0.05 <0.01 0.01-0.38 
BSO 0.79 0.36 0.47-1.32 
BSO Age 0.99 0.82 0.95-1.04 
TAH  0.65 0.08 0.40-1.05 
TAH Age 0.98 0.35 0.94-1.02 
 
FAMILY HISTORY 
Number of First Degree Relatives with Breast Cancer 
If the woman did not have any first degree relatives with breast cancer, the hazard 
ratio was 0.65 with a p-value of 0.015 (95% CI: 0.46-0.92), which was statistically 
significant.  
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Number of Second Degree Relatives with Breast Cancer 
If the woman did not have a second degree relative with breast cancer, the hazard 
ratio was 0.79 with a statistically significant p-value of 0.025 (95% CI: 0.65-0.97). 
Number of First Degree Relatives with Ovarian Cancer 
If the woman did not have a first degree relative with ovarian cancer, the hazard ratio 
was 0.83 with a p-value of 0.69 (95% CI: 0.33-2.06), which was not statistically significant. 
Number of Second Degree Relatives with Ovarian Cancer 
If the woman did not have a second degree relative with ovarian cancer, the hazard 
ratio was 0.91 with a non-statistically significant p-value of 0.71 (95% CI: 0.55-1.51).  
 
Table 25: Family History Univariable Cox Proportional Hazard Model 
Variable Hazard Ratio P-Value Confidence Interval (95%) 
FDR Breast Cancer 0.65 <0.02 0.46-0.92 
SDR Breast Cancer 0.79 <0.03 0.65-0.97 
FDR Ovarian Cancer 0.83 0.69 0.33-2.06 
SDR Ovarian Cancer 0.91 0.71 0.55-1.51 
 
PRIMARY TUMOR CHARACTERISTICS 
Estrogen Receptor Status 
If the ER tumor status was positive, the hazard ratio was 1.45 with a statistically 
interesting p-value 0.096 (95% CI: 0.94-2.20).  
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Progesterone Receptor Status 
If the PR tumor status was positive, the hazard ratio was 1.46 with a p-value of 0.070 
(95% CI: 0.97-2.21), which was statistically interesting.  
Her2/neu Status 
If the Her2/neu status was positive, the hazard ratio was 0.63 and had a p-value of 
0.25 (95% CI: 0.29-1.38), which was not statistically significant. 
Pathology of Tumor 
The pathology of the primary tumor had a hazard ratio of 0.93 and a p-value of 0.58 
(95% CI: 0.73-1.19), which was not statistically significant.  
Previous Biopsy/Previous Biopsy Number 
If the woman ever had a previous biopsy, the hazard ratio was 1.41 with a p-value of 
0.193 (95% CI: 0.84-2.36), which was statistically interesting. The number of previous 
biopsies had a hazard ratio of 1.07 and a non-statistically significant p-value of 0.45 (95% 
CI: 0.90-1.27). 
Tumor Size 
The size of the primary tumor had a hazard ratio of 1.04 and a p-value of 0.60 (95% 
CI: 0.91-1.18), which was not statistically significant.  
Grade of Tumor 
The grade of the primary tumor had a hazard ratio of 0.85 with a p-value of 0.38 
(95% CI: 0.60-1.21), which was not statistically significant.  
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Lymphovascular Invasion 
If the woman had lymphovascular invasion at the time of the primary breast cancer 
diagnosis, the hazard ratio was 1.48 with a statistically interesting p-value of 0.064 (95% CI: 
0.98-2.25).  
 
Table 26: Primary Tumor Characteristics Cox Proportional Hazard Model 
Variable Hazard Ratio P-Value Confidence Interval (95%) 
ER Status 1.44 <0.10 0.94-2.20 
PR Status 1.46 <0.10 0.97-2.21 
Her2/neu Status 0.63 0.25 0.29-1.38 
Pathology 0.93 0.58 0.73-1.19 
Previous Biopsy 1.41 0.19 0.84-2.36 
Previous Biopsy Number 1.07 0.45 0.90-1.27 
Tumor Size 1.04 0.60 0.91-1.18 
Grade 0.85 0.38 0.60-1.21 
Lymphovascular Invasion 1.48 0.06 0.98-2.25 
 
TREATMENT 
Radiation Therapy 
If the woman was treated with radiation at the primary breast cancer diagnosis, the 
hazard ratio was 1.54 with a statistically interesting p-value of 0.054 (95% CI: 0.99-2.39).  
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Chemotherapy 
If the woman was treated with chemotherapy at the time of the primary breast cancer 
diagnosis, the hazard ratio was 1.32 with a non-statistically significant p-value of 0.29 (95% 
CI: 0.79-2.23). 
Tamoxifen Use/Tamoxifen Length of Use 
If the woman used Tamoxifen, the hazard ratio was 1.07 and the p-value was 0.76, 
which was not statistically significant (95% CI: 0.71-1.60). The length of time the woman 
took Tamoxifen had a hazard ratio of 1.04 and a non-statistically significant p-value of 0.62 
(95% CI: 0.90-1.20). 
 
Table 27: Treatment Univariable Cox Proportional Hazard Model 
Variable Hazard Ratio P-Value Confidence Interval (95%) 
Radiation Exposure 1.54 0.05 0.99-2.39 
Chemotherapy 1.32 0.29 0.79-2.23 
Tamoxifen Use 1.07 0.76 0.71-1.60 
Tamoxifen Use Length 1.04 0.62 0.90-1.20 
 
 
MULTIVARIABLE ANALYSIS 
After selecting the potentially interesting covariates by using univariable analyses, a 
stepwise multivariable Cox Proportional Hazard model was performed to build a final 
parsimonious multivariable model with only significant covariates (with adjustments for 
other covariates). The first multivariable analysis included all the potentially interesting 
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variables with a point of entry of 0.1. There were 37 failures with this model and not the 97 
failures expected. The failures indicate how many women developed contralateral breast 
cancer.  The results are summarized in Table 28. 
 
Table 28: Multivariable Cox Proportional Hazard Model: All Interesting Covariables with 
Point of Entry = 0.1 
Variable Hazard Ratio P-Value Confidence Interval (95%) 
Radiation Exposure 2.02 0.09 0.90-4.53 
NumFDRBreast 0.50 0.03 0.27-0.95 
DiagAge 1.07 0.03 1.01-1.13 
ProphylacticMastectomy 0.11 0.03 0.01-0.79 
 
It was determined that the covariable ‘Age at Menopause’ had 60 failures and the 
covariable ‘Age at First Birth’ had 80 failures due to missing data.  Multivariable Cox 
Proportional Hazard model was repeated without including age at menopause so as to retain 
a reasonable sample size. In this model, there were 59 failures. We ran this model with a 
point of entry at 0.1. The results of running this model are summarized in Table 29. 
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Table 29: Multivariable Cox Proportional Hazard Model, Excluding Age of Menopause 
Point of Entry =0.1  
Variable Hazard Ratio P-Value Confidence Interval (95%) 
Prophylactic Mastectomy 0.06 0.005 0.00-0.42 
NumFDRBreast 0.44 0.002 0.26-0.75 
DiagAge 1.06 0.011 1.01-1.11 
AgeFirstBirth 1.04 0.080 1.00-1.09 
 
We then reran the stepwise multivariable Cox Proportional Hazard model excluding 
both age at menopause and age at first birth. In this model, there were 73 failures. This 
model was also run with a point of entry at 0.1. The results are summarized in Table 30. 
 
Table 30: Multivariable Cox Proportional Hazard Model, Excluding Age of Menopause and 
Age at First Birth,  Point of Entry =0.1 
Variable Hazard Ratio P-Value Confidence Interval (95%) 
Prophylactic Mastectomy 0.06 0.004 0.01-0.41 
NumFDRBreast 0.53 0.007 0.34-0.84 
DiagAge 1.05 0.030 1.00-1.09 
NumSDRBreast 0.74 0.017 0.57-0.95 
ER 1.65 0.060 0.98-2.78 
OCPUse 0.62 0.073 0.36-1.05 
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We then reran the stepwise multivariable Cox Proportional Hazard Model excluding 
age at menopause, age at first birth, and total abdominal hysterectomy due to a low number 
of failures in these covariables. In this new model there were 85 failures. We used a point of 
entry at 0.1 and 0.05, which gave the same results. The results are summarized in Table 31. 
 
Table 31: Multivariable Cox Proportional Hazard Model, Excluding Age at Menopause, Age 
at First Birth, and Total Abdominal Hysterectomy, Point of Entry =0.1 and 0.05 
Variable Hazard Ratio P-Value Confidence Interval (95%) 
Prophylactic Mastectomy 0.05 0.003 0.01-0.37 
NumFDRBreast 0.50 0.002 0.32-0.77 
DiagAge 1.06 0.004 1.01-1.10 
NumSDRBreast 0.71 0.005 0.56-0.90 
ER 1.65 0.038 1.03-2.64 
 
 
KAPLAN-MEIER CURVES 
After univariable Cox Proportional Hazard Model was performed, Kaplan-Meier 
curves and log-rank tests were calculated on the statistically interesting or statistically 
significant predictors, classified as having a p-value <0.2. Figure 6 shows the Kaplan-Meier 
curve for the time to develop contralateral breast cancer, with a median time at 24.5 years 
after the first primary diagnosis.  
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Figure 6: Kaplan-Meier Curve for Time to Contralateral Breast Cancer Development 
 
 
 
 
 
 
 
 
 
 
 
Figure 7A shows the Kaplan-Meier curve for age at the first primary diagnosis when 
divided into three groups. Group one is women who were diagnosed with their primary 
breast cancer under the age of 30. Group two is women who were diagnosed with their 
primary breast cancer between the ages of 30 and 40. Group three is women who were 
diagnosed with their primary breast cancer between the ages of 40 and 50. The p-value for 
this curve was 0.14. Figure 7B shows the Kaplan-Meier curve for age at the first primary 
diagnosis when divided into two groups. Group one is women who were diagnosed under 
the age of 40 and group two is women who were diagnosed between the ages of 40 and 50. 
The p-value for this curve was 0.01. 
 
 
Median Time to 
Develop CBC = 24.5 
years 
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Figure 7: Kaplan-Meier Curves for Age at Primary Diagnosis in Different Subgroups 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A: Log-Rank P-Value = 0.14 
B: Log-Rank P-Value = 0.01 
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Figure 8A shows the Kaplan-Meier curve for age at first live birth when divided into 
three groups. Group one is women who had their first live birth under the age of 20 years 
old. Group two is women who had their first live birth between the ages of 20 and 30 and 
group three is women who had their first live birth between the ages of 30 and 43. The p-
value for this curve was 0.18. Figure 8B shows the Kaplan-Meier curve for age at first birth 
when divided into two groups. Group one is women who had their first live birth under the 
age of 35 and group two is women who had their first live birth over the age of 35. The p-
value for this curve was 0.12.  
 
Figure 8: Kaplan-Meier Curves for Age at First Birth in Different Subgroups 
 
 
 
 
 
 
 
 
 
 
 
 
 
A: Log-Rank P-Value = 0.18 
B: Log-Rank P-Value = 0.12 
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Figure 9 shows the Kaplan-Meier curve for whether a woman ever used oral 
contraceptive pills or not. The p-value for this curve was 0.07. 
 
Figure 9: Kaplan-Meier Curve for Oral Contraceptive Use 
 
 
 
 
 
 
 
 
 
 
Figure 10A shows the Kaplan-Meier curve for age at which menopause occurred 
when divided into four groups. Group one is women who experienced menopause under the 
age of 30. Group two is women who experienced menopause between the ages of 30 and 40. 
Group three is women who experienced menopause between the ages of 40 and 50. Group 
four is women who experienced menopause between the ages of 50 and 58. The p-value for 
this curve was 0.0005. Figure 10B shows the Kaplan-Meier curve for age at which 
menopause occurred when divided into two groups. Group one is women who experienced 
menopause under the age of 40 and group two is women who experienced menopause over 
the age of 40. The p-value for this curve was 0.0020. 
Log-Rank P-Value = 0.07 
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Figure 10: Kaplan-Meier Curves for Age at Menopause in Different Subgroups 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11 shows the Kaplan-Meier curve for women who had a total abdominal 
hysterectomy and women who did not have a total abdominal hysterectomy. The p-value for 
this curve was 0.08. 
A: Log-Rank P-Value = 0.0005 
B: Log-Rank P-Value = 0.0020 
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Figure 11: Kaplan-Meier Curve for Total Abdominal Hysterectomy 
 
 
 
 
 
 
 
 
 
Figure 12 shows the Kaplan-Meier curve for whether the estrogen receptor status 
was positive or negative. The p-value for this curve was 0.09. 
 
Figure 12: Kaplan-Meier Curve for ER Status  
 
 
 
 
 
 
 
 
Log-Rank P-Value = 0.08 
Log-Rank P-Value = 0.09 
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Figure 13 shows the Kaplan-Meier curve for whether the progesterone status of the 
primary tumor was positive or negative. The p-value for this curve was 0.06. 
 
Figure 13: Kaplan-Meier Curve for PR Status 
 
 
 
 
 
 
 
 
Figure 14 shows the Kaplan-Meier curve for whether a woman had a previous biopsy 
or not. The p-value of this curve is 0.18. 
 
Figure 14: Kaplan-Meier Curve for Previous Biopsy 
 
 
 
 
 
 
 
Log-Rank P-Value = 0.06 
Log-Rank P-Value = 0.18 
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Figure 15 shows the Kaplan-Meier curve for whether the patient received radiation 
therapy as part of the treatment for their primary breast cancer. The p-value for this curve is 
0.049. 
 
Figure 15: Kaplan-Meier Curve for Radiation Exposure 
 
 
 
 
 
 
 
 
 
Figure 16 shows the Kaplan-Meier curve for whether a woman had a prophylactic 
mastectomy or not. The p-value for this curve was <0.0001. 
 
 
 
 
 
 
 
Log-Rank P-Value = 0.049 
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Figure 16: Kaplan-Meier Curve for Prophylactic Mastectomy 
 
 
 
 
 
 
 
 
Figure 17 shows the Kaplan-Meier curve for whether the woman had 
lymphovascular invasion at the time of her primary breast cancer diagnosis or not. The p-
value for this curve was 0.06. 
 
Figure 17: Kaplan-Meier Curve for Lymphovascular Invasion 
 
 
 
 
 
 
 
 
 
Log-Rank P-Value = 0.06 
Log-Rank P-Value = <0.0001 
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Figure 18A shows the Kaplan-Meier curve for the number of first degree relatives a 
woman had when divided into two groups. Group one is women who had no first degree 
relatives with breast cancer and group two is women who had first degree relatives with 
breast cancer. The p-value for this curve is 0.028. Figure 18B shows the Kaplan-Meier curve 
for the number of first degree relatives a woman had when divided into two different groups. 
Group one is women who had one or less than one first degree relative with breast cancer 
and group two is women who had greater than one first degree relative with breast cancer. 
The p-value for this curve was 0.08. 
 
Figure 18: Kaplan-Meier Curves for Number of First Degree Relatives with Breast Cancer 
 
 
 
 
 
 
 
 
 
 
 
 
 
A: Log-Rank P-Value = 0.028 
B: Log-Rank P-Value = 0.08 
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Figure 19A shows the Kaplan-Meier curve for the number of second degree relatives 
a woman had with breast cancer divided into two groups. Group one is women who had no 
second degree relatives with breast cancer and group two is women who had at least one 
second degree relative with breast cancer. The p-value for this curve was 0.0264. Figure 19B 
shows the Kaplan-Meier curve for the number of second degree relatives with breast cancer 
a woman had when divided into two different groups. Group one is women who had one or 
less than one second degree relative with breast cancer and group two is women who had 
more than one second degree relative with breast cancer. The p-value for this curve was 
0.11. 
 
Figure 19: Kaplan-Meier Curves for Number of Second Degree Relatives with Breast 
Cancer 
 
 
 
 
 
 
 
  
 
 
 
A: Log-Rank P-Value = 0.0264 
B: Log-Rank P-Value = 0.11 
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After the multivariable Cox Proportional Hazard model was ran, recursive 
partitioning was performed using predictive covariables that classified the women by 
whether or not they developed contralateral breast cancer by creating a decision tree. A 
Kaplan-Meier curve was then used to determine which women were at a low risk to develop 
contralateral breast cancer, which women were at a medium risk to develop contralateral 
breast cancer, and which women were at a high risk to develop contralateral breast cancer. 
When the RPART model was run, it was determined that the estrogen receptor status of the 
primary tumor was confounding with another statistically significant variable and therefore 
was not included in the final RPART tree. The most statistically significant covariable was 
prophylactic mastectomy. There was one woman who developed contralateral breast cancer 
after having a prophylactic mastectomy out of 115 women who had prophylactic 
mastectomies. Their estimated rate to develop contralateral breast cancer relative to our 
study population was 0.12. If the woman did not have a prophylactic mastectomy and she 
had at least one first degree relative with breast cancer, her estimated risk to develop 
contralateral breast cancer relative to our study population was 0.823. This applied to 30 
women out of 170 women who had at least one first degree relative with breast cancer. If the 
woman did not have a prophylactic mastectomy, did not have any first degree relatives with 
breast cancer and was diagnosed with her primary breast cancer over the age of 46 years, her 
estimated rate to develop contralateral breast cancer relative to our study population was 2.7. 
This applied to 18 out of 54 women. If the woman did not have a prophylactic mastectomy, 
did not have any first degree relatives with breast cancer, was diagnosed with her first 
primary before the age of 46 and had a second degree relative with breast cancer, her 
estimated rate to develop contralateral breast cancer relative to our study population was 
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0.86 and if she did not have a second degree relative with breast cancer her estimated rate 
was 1.9. 
 
Figure 20: RPART model 
 
 
 
 
 
Node 1 
Node 2 
Node 3 Node 4 
Node 5 
Prophylactic Mastectomy = Yes 
Prophylactic Mastectomy = No 
NumFDRBreast = 1,2,3,5 
NumFDRBreast = 0 
Diagnosis Age <46 
Diagnosis Age >= 46 
NumSDRBreast=1,2,3,4,5 
NumSDRBreast = 0 
Figure 20: The top node of the decision tree begins with all 97 women with contralateral breast cancer out of the 572 women in the 
cohort. The 97 women have an estimated rate of 1 to develop contralateral breast cancer relative to the study population. Node 1 
had the one woman who had a prophylactic mastectomy and developed contralateral breast cancer with an estimated rate to 
develop CBC of 0.12 relative to the study population. Node 2 shows that this group of women has a 0.83 estimated rate to develop 
CBC relative to the study population. Node 3 shows that this group of women has a 0.86 estimated rate to develop CBC relative to 
the study population. Node 4 shows that this group of women has a 1.9 estimated rate to develop CBC relative to the study 
population. Node 5 shows that this group of women has 2.7 estimated rate to develop CBC relative to the study population. 
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Based on the RPART model, the five terminal nodes were divided into three 
different subgroups. Subgroup 1 contains node 1, which contains the one woman who 
developed contralateral breast cancer after undergoing a prophylactic mastectomy. Subgroup 
2 contains nodes 2 and 3. Node 2 is the women who did not have a prophylactic mastectomy 
and had at least one first degree relative with breast cancer. Node 3 is the women who did 
not have a prophylactic mastectomy, had no first degree relatives with breast cancer, were 
diagnosed with their primary breast cancer under the age of 46 and had at least one second 
degree relative with breast cancer. Subgroup 3 is nodes 4 and 5. Node 4 is the women who 
did not have a prophylactic mastectomy, had no first degree relatives with breast cancer, 
were diagnosed with their primary breast cancer under the age of 46, and had no second 
degree relatives with breast cancer. Node 5 is the women who did not have a prophylactic 
mastectomy, had no first degree relatives with breast cancer, and were diagnosed with their 
first primary breast cancer over the age of 46. The average time to contralateral breast 
cancer diagnosis for subgroup two is 31 years after the primary breast cancer diagnosis. The 
average time to contralateral breast cancer diagnosis for subgroup three is 15 years after the 
primary breast cancer diagnosis. The Kaplan-Meier curve based on the RPART model 
shows that subgroup one had a low risk to develop contralateral breast cancer. Subgroup two 
had a medium risk to develop contralateral breast cancer and subgroup three had a high risk 
to develop contralateral breast cancer. 
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Figure 21: Kaplan-Meier Curve Based on RPART with Nodes Divided into 3 Subgroups 
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Figure 21: The low risk group contains node 1 from the RPART tree which contains the one woman who developed contralateral 
breast cancer after having a prophylactic mastectomy. The medium risk group contains nodes 2 & 3. Node 2 is women who did 
not have a prophylactic mastectomy and had at least one first degree relative with breast cancer. Node 3 is women who did not 
have a prophylactic mastectomy, had no first degree relatives with breast cancer, were diagnosed under the age of 46 years old, 
and had at least one second degree relative with breast cancer. The high risk group contains nodes 4 & 5. Node 4 is women who 
did not have a prophylactic mastectomy, had no first degree relatives with breast cancer, were diagnosed under the age of 46 
years old, and had no second degree relatives with breast cancer. Node 5 is women who did not have a prophylactic 
mastectomy, had no first degree relatives with breast cancer, and were diagnosed over the age of 46 years old. 
69 
 
DISCUSSION 
 
 After an extensive literature review, we have not discovered any research that 
focused on a BRCA negative woman’s risk to develop a second primary breast cancer after 
being diagnosed with a primary breast cancer under the age of 50 when they have a strong 
family history of breast and/or ovarian cancer. One of the aims of this study was to identify 
the incidence of contralateral breast cancer in a population of women who had a previous 
primary invasive breast cancer diagnosed under the age of 50, a BRCAPro risk assessment 
model of greater than 10%, and who tested negative for a mutation in the BRCA1 and 
BRCA2 genes. A second aim of this study was to identify predictors of contralateral breast 
cancer in this population of women. There have been numerous other studies that have 
identified predictors of contralateral breast cancer in women with a primary breast cancer 
who have not been tested for a BRCA1/2 mutation. There have been many other studies that 
have identified predictors of contralateral breast cancer in women with a BRCA1 or BRCA2 
mutation. There have been no studies looking at predictors of contralateral breast cancer in 
our patient population. The goal of this study was to identify the predictors of contralateral 
breast cancer in our specific cohort as well as to identify the incidence of contralateral breast 
cancer in the cohort. 
 This study population had an incidence of contralateral breast cancer of 17%. 
Approximately 30% of the contralateral breast cancer subpopulation had synchronous 
contralateral breast cancer and 70% had metachronous contralateral breast cancer.  
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DEMOGRAPHIC AND LIFESTYLE COVARIABLES 
Ethnicity 
Ethnicity of the women in our cohort did not have statistical significance when 
determining predictors of contralateral breast cancer. Our study population was mostly Non-
Hispanic White, which skews the data and makes it less significant. Several other studies 
also had a higher number of Non-Hispanic Whites in their population and also found 
ethnicity to not be statistically significant when looking at the risk of contralateral breast 
cancer in women who have a BRCA1 or BRCA2 mutation as well as in cohorts where 
genetic testing was not performed [2,18,28,35]. However, Gao et al. (2003) found that being 
African-American increased one’s risk to develop contralateral breast cancer [1]. Gao’s 
study contained 6% African-American women while our study contained 9% and we did not 
see the same trend that being of African-American ethnicity increased a woman’s risk to 
develop contralateral breast cancer. More studies are needed to determine if being African-
American increases a woman’s risk to develop contralateral breast cancer. 
Age at Primary Diagnosis 
The age at the primary breast cancer diagnosis was found to be statistically 
significant and a predictor of contralateral breast cancer, with a p-value of 0.004. In our 
study, being over the age of 46 at the time of the first diagnosis, places a woman in the high 
risk category to develop contralateral breast cancer. This is consistent with some published 
literature regarding age at the primary breast cancer diagnosis and the risk to develop 
contralateral breast cancer. Several studies have shown that being younger at the age of the 
first primary, defined as before 50 years of age, increased a woman’s risk to develop 
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contralateral breast cancer [8,15,17,18,19,20,21,24,28]. This was also found in women who 
tested positive for a BRCA1 or BRCA2 mutation [2,23,25].  
BRCAPro Risk Assessment Number 
The BRCAPro risk assessment number was not found to be a statistically significant 
predictor of contralateral breast cancer in our study population. There have not been many 
studies that used the BRCAPro risk assessment number as a covariable in determining risk 
for breast cancer or for contralateral breast cancer risk. Ready et al. (2009) looked at the 
BRCAPro model and found that it overestimates the risk to carry a mutation in women who 
have bilateral breast cancer, especially if these women were diagnosed over the age of 40 
years [33]. However, this study did not look at the BRCAPro risk assessment number as a 
predictor of contralateral breast cancer as our study did. More studies are needed to 
determine if having a high BRCAPro risk assessment number is a predictor of contralateral 
breast cancer. 
Ashkenazi Jewish Ancestry 
Ashkenazi Jewish ancestry was not found to be a significant predictor of 
contralateral breast cancer in our study cohort. Malone et al. (2010) also found that being of 
Jewish ancestry did not influence the risk of developing a contralateral breast cancer [2]. 
Malone’s study had a large cohort of 52, 536 women of which 162 were of Jewish ancestry, 
which is approximately 0.31% of their population. Our cohort had 70 out of 572 women 
who were of Ashkenazi Jewish ancestry, which computes to approximately 12.24% of the 
population. Because of the small number of Ashkenazi Jewish women in both Malone’s 
study and our study, it is difficult to determine if being of Ashkenazi Jewish ancestry does  
increase one’s risk to develop contralateral breast cancer or not. In the future, more studies 
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should look at Ashkenazi Jewish ancestry to determine if it is a predictor of contralateral 
breast cancer. 
Smoker/Smoking Length 
Our study did not find a statistically significant risk to develop contralateral breast 
cancer when looking at whether a woman ever smoked or not. This was consistent with 
other published studies which also did not find smoking to increase the risk to develop 
contralateral breast cancer.  Bernstein et al. (2002) and Li et al. (2011) found smoking to not 
be a statistically significant predictor of contralateral breast cancer [20,28]. Knight et al. 
(2009) researched the effect of smoking and alcohol on the risk to develop contralateral 
breast cancer and found that a history of smoking did not increase a woman’s risk to develop 
contralateral breast cancer [27]. They also found that the length of time a woman smoked 
did not increase a woman’s risk to develop contralateral breast cancer either [27]. In our 
study, the length of time a woman smoked was also found to not be a predictor of 
contralateral breast cancer, consistent with Knight et al.’s (2009) findings. 
Alcohol Use 
Whether a woman ever drank alcohol was not a statistically significant predictor of 
contralateral breast cancer in our cohort population. This was inconsistent with the one 
published study that looked at the relationship between alcohol consumption and 
contralateral breast cancer risk. Knight et al. (2009) found that drinking alcohol increases the 
risk to develop contralateral breast cancer [27]; however, there have not been many other 
studies that have looked at the risk of contralateral breast cancer in women who consume 
alcohol. Knight’s study looked at 2,107 women of whom 708 had contralateral breast cancer 
Of the 2,107 total population, 1,277 women reported drinking, which is approximately 
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60.61% of the total population. Our study had 350 of 572 women, who reported drinking, 
which is approximately 61.19% of the total population. Both studies had almost identical 
percentages of women who reported drinking alcohol, but two statistically different 
outcomes. Therefore, we propose that more research needs to be done on the effect of 
drinking alcohol and the risk to develop contralateral breast cancer. 
Body Mass Index (BMI) 
In our cohort, body mass index at the time of the primary diagnosis was not found to 
increase a woman’s risk to develop contralateral breast cancer. This is consistent with the 
published literature studying the effects of body mass index on the risk to develop 
contralateral breast cancer. Brooks et al. (2011) found that a woman’s body mass index at 
the time of diagnosis of the first primary was not a predictor of contralateral breast cancer 
diagnosis [29]. Because of the small number of studies looking at body mass index and the 
risk to develop contralateral breast cancer, future studies should also look at this variable to 
determine if it is a predictor of contralateral breast cancer or not, although the current trend 
indicates that this is not a significant predictor. 
 
REPRODUCTIVE RISK FACTORS 
Age at Menarche 
The age at which a woman experienced menarche was not a significant predictor of 
contralateral breast cancer in our population. This was not consistent with the published 
literature regarding age at menarche and contralateral breast cancer risk. Poynter et al. 
(2010) and Largent et al. (2007) found that a younger age at menarche, defined as before 13 
years of age, increased a woman’s risk to develop contralateral breast cancer [5,30]. Both of 
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these studies had significantly larger cohort’s than our study had, making it more likely that 
a younger age of menarche does, in fact, increase a woman’s risk to develop contralateral 
breast cancer even though our study did not have similar findings. More studies are needed 
to confirm or dispute if the age of menarche is a predictor of contralateral breast cancer in a 
patient population similar to ours. 
Parity/Age at First Full Term Birth 
We did not find an increased risk for contralateral breast cancer based on whether a 
woman had ever had a full term birth or not; however, we did find that the age at which a 
woman had her first full term birth was a significant predictor of contralateral breast cancer 
in univariable analysis, but not in multivariable anaylsis. This is inconsistent with the 
published literature. Poynter et al. (2010) and Largent et al. (2007) did not find the age at 
first full term birth to increase the risk of contralateral breast cancer, but they did find that a 
higher number of full term births decreased a woman’s risk [5,30]. This is opposite of our 
study’s findings. The cohorts in the two previously published studies were larger than our 
cohort and therefore could carry more statistical significance. These variables should be 
studied in future cohorts with a similar patient population that have a larger population of 
women to determine the clinical validity of the findings. 
Experienced Menopause/Age at Menopause 
Whether a woman had ever experienced menopause was not found to be a predictor 
of contralateral breast cancer; however, the age at which a woman experienced menopause 
was found to be statistically interesting in the univariable analysis. This was then determined 
to not achieve statistical significance in the multivariable analysis due to missing 
information regarding the age at which women were experiencing menopause. The final 
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results are consistent with the current literature. Largent et al. (2007) also found that age at 
the time of menopause did not increase a woman’s risk to develop contralateral breast 
cancer [30]. Poynter et al. (2010) found that experiencing menopause did not increase or 
decrease a woman’s risk to develop contralateral breast cancer [5]. Both studies are 
consistent with our findings that experiencing menopause and the age at which a woman 
experiences menopause are not significant predictors of contralateral breast cancer. 
Hormone Replacement Use/Length of Use of Hormone Replacement 
The length of use of hormone replacement therapy and if a woman ever took 
hormone replacement therapy drugs was not found to increase her risk to develop 
contralateral breast cancer. This was consistent with the limited research regarding hormone 
replacement therapy and the risk for contralateral breast cancer. Figueiredo et al. (2010) also 
found that using hormone replacement therapy does not increase the risk to develop 
contralateral breast cancer [31]; however, there are not many studies that look at hormone 
replacement therapy as a predictor of contralateral breast cancer. Future research should 
study the effect of hormone use on the risk to develop contralateral breast cancer, as this 
variable has not been studied much when looking at predictors of contralateral breast cancer.  
Oral Contraceptive Pills Use/Length of Use of Oral Contraceptive Pills  
If a woman ever used oral contraceptive pills was found to be statistically interesting 
in the univariable analysis, but this was not found to be statistically significant in the 
multivariable analysis. The length of time that the women took oral contraceptive pills was 
not found to cause an increase the risk to develop contralateral breast cancer in our cohort. 
This is consistent with the published literature. Figueiredo et al. (2010) looked specifically at 
oral contraceptive use and the risk of contralateral breast cancer and did not find an 
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increased risk for contralateral breast cancer after using oral contraceptive pills [31]. This 
same study also looked at the length of time that oral contraceptive pills were used and 
found no increase in contralateral breast cancer risk with longer length of use [31]. More 
studies are needed to determine if oral contraceptive pill use is in fact not correlated to an 
increased risk for contralateral breast cancer. 
 
RISK REDUCING SURGERIES 
Prophylactic Mastectomy 
Having a prophylactic mastectomy significantly reduced our cohorts risk to develop 
contralateral breast cancer with a p-value of 0.003; however, one woman in our cohort did 
develop contralateral breast cancer after having a prophylactic mastectomy. This is 
consistent with the published literature regarding the risk of contralateral breast cancer after 
undergoing a prophylactic mastectomy [7,17,18,23,36]. As prophylactic mastectomy was 
our most statistically significant variable, this shows how significant a prophylactic 
mastectomy is in reducing a woman’s risk to develop contralateral breast cancer. 
Bilateral Salpingo-Oophorectomy/Age at Bilateral Salpingo-Oophorectomy 
Having a bilateral salpingo-oophorectomy was not found to be a predictor of 
contralateral breast cancer in our patient population. The age at which a woman underwent a 
bilateral salpingo-oophorectomy also did not influence her risk to develop contralateral 
breast cancer. This is inconsistent with the published research regarding the risk to develop 
contralateral breast cancer after undergoing a bilateral salpingo-oophorectomy. Metcalfe et 
al. (2011) and van Sprundel et al. (2005) found a decrease in risk for contralateral breast 
cancer after having a bilateral salpingo-oophorectomy [24,36]. Both of these studies 
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researched the effect of having a bilateral salpingo-oophorectomy on the risk of contralateral 
breast cancer in a population of women who had tested positive for a BRCA1 or BRCA2 
mutation. Our population contained only BRCA1/2 negative women. This could explain the 
differences in our findings. More studies of BRCA1/2 negative women are needed to 
confirm or reject our findings that showed that bilateral salpingo-oophorectomy was not a 
predictor of contralateral breast cancer. 
Total Abdominal Hysterectomy/Age at Total Abdominal Hysterectomy 
Having a total abdominal hysterectomy was found to be a predictor of contralateral 
breast cancer in our patient population using univariable analysis; however, this was found 
to not be statistically significant in the multivariable analysis. The age at which a woman 
had a total abdominal hysterectomy was not found to be a risk factor to develop contralateral 
breast cancer in our patient population. To our knowledge, there are no other studies looking 
specifically at the risk of contralateral breast cancer in relation to a woman having a total 
abdominal hysterectomy. The published studies look at the interaction between bilateral 
salpingo-oophorectomy and contralateral breast cancer, but not total abdominal 
hysterectomy. More studies need to be performed looking at this variable to determine if it 
is, in fact, not a predictor of contralateral breast cancer. 
 
FAMILY HISTORY 
Number of First Degree Relatives with Breast Cancer 
The number of first degree relatives with breast cancer that a woman has does 
influence her risk to develop contralateral breast cancer. This was found to be a statistically 
significant predictor of contralateral breast cancer in the univariable and multivariable Cox 
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Proportional Hazard model, with a p-value of 0.002. Several other studies also found an 
increase in contralateral breast cancer risk when a patient has a family history of breast 
cancer, whether or not the patient also had a BRCA1 or BRCA2 mutation [2,8,19,21,24,25]. 
These studies are consistent with our findings that having a family history of breast cancer is 
a predictor of contralateral breast cancer. 
Number of Second Degree Relatives with Breast Cancer 
The number of second degree relatives with breast cancer that a patient in our cohort 
does influence her risk to develop contralateral breast cancer. This was found to be a 
statistically significant factor for developing contralateral breast cancer after the univariable 
and the multivariable Cox Proportional Hazard models were run, with a p-value of 0.005. 
Several other studies found that having a family history of breast cancer increased a 
patient’s risk to develop a contralateral breast cancer, regardless of whether the patient had a 
mutation in BRCA1 or BRCA2 [8,19,21,24,25]. The findings of these studies are consistent 
with our results in our patient population as well. 
Number of First and Second Degree Relatives with Ovarian Cancer 
The number of first and second degree relatives with ovarian cancer that a woman 
had was not found to increase or decrease her risk to develop contralateral breast cancer in 
our cohort. There were no other studies that looked into a family history of ovarian cancer as 
a predictor of contralateral breast cancer. Future studies should look at the interaction 
between a family history of ovarian cancer and the risk to develop contralateral breast 
cancer to help determine the significance of the results in our study. 
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PRIMARY TUMOR CHARACTERISTICS 
Estrogen Receptor Status 
Having a positive estrogen receptor status of the primary tumor was found to be a 
predictor of contralateral breast cancer in our patient population. This was also found to be 
statistically significant in the multivariable analysis with a p-value of 0.038. This is not 
consistent with the current research regarding estrogen receptor status as a predictor of 
contralateral breast cancer. Kollias et al. (1999) and Metcalfe et al. (2011) did not find 
estrogen receptor status to be a predictor of contralateral breast cancer [19,24]. Both 
previous studies had large cohorts compared to our population size. Metcalfe et al. (2011) 
studied only women with a BRCA1/2 mutation, while Kollias et al. (1999) studied all 
women regardless of BRCA1/2 mutation status. Future studies with a larger cohort should 
re-evaluate the effect of estrogen receptor status on contralateral breast cancer risk in a 
similar patient population to ours. 
Progesterone Receptor Status 
Having a positive progesterone receptor status of the primary tumor was found to be 
a predictor of contralateral breast cancer in our cohort in univariable analysis; however, this 
was not found to be statistically significant using the multivariable analysis model. This was 
found to be consistent with the published literature. Kollias et al. (1999) and Metcalfe et al. 
(2011) also found the progesterone status of the primary tumor to not be a predictor of 
contralateral breast cancer [19,24]. These two studies had larger patient populations than our 
study. They also looked at different subsets of patients. Kollias et al. (1999) looked at 
women who had not had genetic testing while Metcalfe et al. (2011) studied women who 
were BRCA1/2 positive [19,24]. Due to the differing nature of our cohort and these two 
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cohorts, future studies should look at progesterone receptor status in different patient 
populations to identify if it is a predictor of contralateral breast cancer or not. 
Her2/neu Status 
The Her2/neu status of the primary tumor was not found to influence the risk of a 
woman developing contralateral breast cancer in our patient population. No other studies 
looked at Her2/neu as a predictor of contralateral breast cancer. Future studies should look at 
this predictor to see if it increases the risk of contralateral breast cancer in a similar patient 
population. 
Pathology of Tumor 
The pathology of the primary tumor was not found to be a predictor of contralateral 
breast cancer in our patient population. This is mostly consistent with the published 
research. Three other studies also found that the pathology subtype of the primary tumor did 
not increase the risk to develop contralateral breast cancer [8,17,20]. However, Yi et al. 
(2009) and Kollias et al. (1999) found an increase in contralateral breast cancer risk when 
the pathology of the primary tumor was invasive lobular carcinoma [18,19]. Yi et al. (2009) 
looked at a similar cohort size and Kollias et al. (1999) had a larger cohort size, but neither 
study looked at their cohort’s BRCA1/2 mutation status. Because of the difference in the 
patient populations of these studies, more research should study the pathology of the 
primary breast cancer tumor to determine if invasive lobular carcinoma, or other pathology 
types, increases a woman’s risk to develop contralateral breast cancer. 
Previous Biopsy/Previous Biopsy Number 
Whether or not a woman had a previous biopsy was found to be a predictor of 
contralateral breast cancer using univariable analysis; however, this was not found to 
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achieve statistical significance in the multivariable analysis. The number of previous 
biopsies that a woman had was not found to be a predictor of contralateral breast cancer. 
Having a previous biopsy was not used as a covariable in any other studies predicting risk 
factors for contralateral breast cancer. More studies are needed to determine if having 
previous biopsies increases a woman’s risk to develop contralateral breast cancer. 
Tumor Size 
The size of the primary tumor was not found to be a predictor of contralateral breast 
cancer in our patient population. This was consistent with the published literature. Kollias et 
al. (1999) also did not find the size of the primary breast cancer tumor to be a predictor of 
contralateral breast cancer [19]. This study looked at women who had not undergone 
BRCA1/2 testing and therefore had a different patient population than our study. More 
studies are needed to determine if the size of the primary breast cancer tumor is a predictor 
of contralateral breast cancer in patient populations similar to ours. 
Grade of Tumor 
The grade of the primary tumor was not found to be a predictor of contralateral 
breast cancer in this cohort. This is mostly consistent with the published research. Kollias et 
al. (1999) did find an increase in contralateral breast cancer risk when the grade of the 
primary breast cancer was one or two, but this did not reach statistical significance in their 
study [19]. Metcalfe et al. (2011) did not find an increase in contralateral breast cancer risk 
with the grade of the primary tumor [24]. More studies are needed to determine if the grade 
of the primary breast cancer tumor is a predictor of contralateral breast cancer, especially in 
a patient population similar to ours. 
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Lymphovascular Invasion 
Lymphovascular invasion was found to be a predictor of contralateral breast cancer 
in our cohort; however, this was not found to be statistically significant in the multivariable 
Cox Proportional Hazard model. The current published literature regarding lymphovascular 
invasion as a risk factor for contralateral breast cancer has found lymphovascular invasion to 
be a risk factor as well as it to not be a risk factor. Metcalfe et al. (2011) and Kirova et al. 
(2005) found that lymphovascular invasion was a predictor of contralateral breast cancer in 
their population [24,25]. Both of these studies looked at lymphovascular invasion as a 
predictor of contralateral breast cancer in women who tested positive for a BRCA1/2 
mutation, unlike our cohort which had BRCA1/2 negative women. Kollias et al. (1999) and 
Vichapat et al. (2011) did not find lymphovascular invasion to be a predictor of contralateral 
breast cancer [19,21]. These two studies did not look at a woman’s BRCA1/2 mutation status 
and found similar results to ours. Future studies are needed to determine which patient 
populations are at an increased risk to develop contralateral breast cancer after having 
lymphovascular invasion with the primary breast cancer diagnosis. 
 
TREATMENT 
Radiation Therapy 
Radiation exposure during the treatment for the primary breast cancer was found to 
be a predictor of contralateral breast cancer; however, this did not achieve statistical 
significance in the multivariable analysis. This is mostly consistent with the current 
published literature. Three different studies also did not find radiation treatment to be a risk 
factor for contralateral breast cancer [20,24,25]. Rubino et al. (2010) and Kollias et al. 
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(1999) found an increase in contralateral breast cancer risk after radiation therapy, but 
neither reached statistical significance [17,19].  Gao et al. studied the risk to develop 
contralateral breast cancer after receiving radiation therapy for the first primary. They found 
that radiation therapy was associated with an increase of contralateral breast cancer being 
diagnosed more than five years after the first primary diagnosis [1]. Our study did not look 
at the relationship between radiation exposure and how it was related to the time to 
contralateral breast cancer development. Future studies are needed to determine if radiation 
therapy for the primary breast cancer increases a woman’s risk to develop contralateral 
breast cancer. 
Chemotherapy 
Chemotherapy to treat the primary breast cancer was not found to be a predictor of 
contralateral breast cancer in our patient population. This is consistent with the published 
literature. Kollias et al. (1999) and Metcalfe et al. (2011) also did not find an increase in 
contralateral breast cancer risk after receiving chemotherapy for the primary breast cancer 
[19,24]. Reding et al. (2010) found a decrease in contralateral breast cancer risk after 
chemotherapy for the first primary breast cancer [37]. Kollias et al. (1999) and Metcalfe et 
al. (2011) results are consistent with our findings. 
Tamoxifen Use/Tamoxifen Length of Use 
The use of Tamoxifen as chemoprevention was not found to be a predictor of 
contralateral breast cancer. The length of time a patient took Tamoxifen was also not found 
to be a predictor of contralateral breast cancer in our patient population. This is consistent 
with the currently published literature regarding contralateral breast cancer risk after a 
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woman takes Tamoxifen. Kollias et al. (1999) and Metcalfe et al. (2011) also did not find an 
increase in contralateral breast cancer risk after the patients took Tamoxifen [19,24].  
 
SUMMARY 
Our study found three different groups that had a low, medium, or high risk to 
develop contralateral breast cancer. We found that having a prophylactic mastectomy gives a 
woman a low risk to develop contralateral breast cancer. Women who did not have a 
prophylactic mastectomy and had at least one first degree relative with breast cancer had a 
medium risk to develop contralateral breast cancer. The medium risk group also included 
women who had not had a prophylactic mastectomy, had no first degree relatives with breast 
cancer, were diagnosed with their primary under the age of 46 and had at least one second 
degree relative with breast cancer. The high risk group included women who had not had a 
prophylactic mastectomy, had no first degree relatives with breast cancer, were diagnosed 
under the age of 46 with their first primary breast cancer and had no second degree relatives 
with breast cancer. The high risk group also included women who did not have a 
prophylactic mastectomy, had no first degree relatives with breast cancer, and were 
diagnosed over with their first primary over the age of 46.  
We looked at a number of other variables, but none of them were statistically 
significant enough to be thought of as predictors of contralateral breast cancer. Surprisingly, 
having a high body mass index did not increase a woman’s risk to develop contralateral 
breast cancer and undergoing a bilateral salpingo-oophorectomy did not decrease a woman’s 
risk to develop contralateral breast cancer, as found in previous studies. Several other risk 
factors that have previously been found to be predictors of contralateral breast cancer were 
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not found to be significant in our study, including: progesterone receptor status, 
lymphovascular invasion of the primary tumor and radiation treatment of the primary tumor. 
Our study found the most significant risk factors to increase the risk for contralateral breast 
cancer to be having a family history of breast cancer, having a young age at diagnosis of the 
primary breast cancer, and having a positive estrogen receptor status of the primary breast 
cancer. Undergoing a prophylactic mastectomy was found to decrease the risk for 
contralateral breast cancer. 
 
STUDY LIMITATIONS 
  There are several limitations of this study. The BRCAPro risk assessment 
probability, used to exclude patients from the study, was run using the CancerGene 
software. This software was updated several times during the time period where our patient 
population was receiving genetic testing. The BRCAPro risk assessment numbers were not 
all performed on the same version of CancerGene and therefore, the numbers could be off if 
recalculated using the newest version of CancerGene.  
There is also a significant ascertainment bias in our population. The entire study 
population consisted of patients who were seen MD Anderson Cancer Center, which has a 
patient population consisting of mostly Non-Hispanic Whites in the upper and middle 
classes. This skews the data to be more representative of this population and not of the 
general population.  
Since the study was a retrospective chart review, there was information missing in 
several of the electronic medical records. Having complete medical histories on all of the 
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women might have given different significant predictors of contralateral breast cancer. A 
prospective study looking at a similar cohort might also yield different results. 
  Another limitation to our study is that the follow-up time was not the same for all of 
the patients. Some patients had long follow-up times while others had very short follow-up 
times. Because of the varying follow-up times, we do not know if some of the unilateral 
breast cancer patients will develop contralateral breast cancer in the future if we followed 
them for long enough.  
 
CONCLUSION 
Based on our research, there should be more studies looking at the predictors of 
contralateral breast cancer in this patient population. Our population had a contralateral 
breast cancer incidence of 17%, which is higher than the general population’s risk to 
develop a primary breast cancer of 12%. Because of this, identifying predictors of 
contralateral breast cancer is important in this population so that clinicians can follow those 
women who are at a higher risk to develop contralateral breast cancer more closely and offer 
them prophylactic mastectomies to reduce their risk. Clinicians should pay special attention 
to those women who have family histories of breast cancer as well as those diagnosed at 
younger ages and with positive estrogen receptor tumors and monitor them closely for 
contralateral breast cancer occurrence.  
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